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The aim of this thesis was to study and develop suitable natural binary hydrogels to 
generate and isolate 3D spheroids from cancer cell lines (HT29 & MCF7) initially 
grown on 2D surfaces. The isolated spheroids were then used for fluorescent gold 
nanocluster (AuNCs) targeting studies. 
 
The major novel findings of this work are: 
 
1. The low melting temperature agar in combination with either collagen or egg 
albumen were slow in generating spheroids and at times inhibited their 
formation. Isolating any formed spheroids from the preparation was difficult with 
disruption and loss of the cluster formation. This combination format was found 
to be unsuitable in the study. 
2. The natural macromolecule based carboxymethyl cellulose in combination with 
gelatine as a gel, gave the ideal outcome in generating spheroids in a short 
time. Its porous structure can be fine-tuned by varying the composition ratio of 
CMC and gelatine and autoclaving the mixture at 121oC. The swelling capacity 
and gelling properties of the CMC+gelatine mixture was ideal for generating 
cancer cell spheroids and harvesting by low centrifugation without destroying 
the clusters.  
3. Spheroids greater than 200µm in diameter displayed hypoxic environment at 
the core detected using hypoxic fluorescent probes. 
4. A novel specific cancer marker calreticulin was detected at increased levels on 
the surface membranes of spheroids using fluorescent gold nanoclusters 
conjugated to anti-calreticulin antibodies. 
5. Specificity of anti-calreticulin antibodies via translocation for surface calreticulin 
was established by testing in a 3D co-culture of preformed endothelial cells 
(HUVECs) on membrane inserts with harvested fixed spheroids at the 
basolateral surface.   
6. The obtained results suggest that the porous natural polymer carboxymethyl 
cellulose in combination with gelatine shows great promise in generating 
harvestable cancer cell spheroids reminiscent of tumours in vivo at low cost, 
high efficiency and robustness.  
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1.1. Nanotechnology in cancer detection 
 
Nanotechnology is science, engineering, and technology which involves 
manipulation of matter on a 'nano' scale (1 to 100 nanometers). The 
nanotechnology devices used for the medical application called nanomedicine. 
In nanomedicine the nanoscale materials, such as biocompatible nanoparticles 
and nanoclusters, used for diagnosis, delivery, sensing in a living organism.   
Cancer starts when tumour suppressor genes in healthy cells stop being 
expressed. This starts a cascade of events, usually involving a number of gene 
mutations which result in loss of proliferation control and the ability to 
metastasise. Cancer conventional detection is done by determination of the 
physical growth changes in the organ using X-rays and CT Scans and 
confirmed using biopsy and even through cell culture (1). These techniques 
come with some limitations, such as decreased sensitivity, and hence the 
detection is possible only after a substantial growth of the cancer cells. Cells 
are within the size range of 2-100 microns, and nanoparticles (NP) are within 
the nanoscale size. Hence, nanoparticles can pass through the cells and reach 
the DNA molecules. There is, therefore, a probability that a defect in the genes 
can be easily identified in vitro and eventually in vivo (2). Cancer detection using 
nanoparticles has shown its potentiality when the cancer is in the developing 
stage. The nanoparticles can travel through the body, detect cancer-linked 
molecular changes, image the changes, release a therapeutic agent and then 
track how efficient the intervention is (3). 
 
1.2. Growth conditions, cell morphology, and population in 
2D and 3D cultures  
 
Many potential approaches in cancer studies have been under research 
including diagnosis and therapeutics. However, most researchers have been 
using monolayer cell cultures, the 2D immobile system.  These forms of culture 
are utilized in the pre-clinical drug testing and use artificial matrices such as 
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glass and plastic. The 2D monolayer cell culture systems, therefore, fail to 
mimic the actual environment in vivo and hence give results that differ 
considerably with what would be expected in the body (4). The process of 
clinical drug screening involves introducing the drug into a cell culture, followed 
by testing the drug in vivo using animals and then proceeding on to clinical 
trials. Only about 5% of the test drugs get through the clinical stage of screening 
(5). Considering that the clinical trial phase is the costliest stage of drug 
development, there is the need to find a remedy for these failures especially 
regarding the toxicity and effectiveness of candidate anti-cancer agents (6). 
The proliferation of cells in the conventional cell culture is usually on a flat 
surface. This setup gives the cells a chance for even growth and proliferation 
because of the equal access of growth factors and nutrients from the culture 
medium. The necrotic cells and other wastes can be removed during the 
change of medium. The main characteristic of cells in the 2D monolayer is that 
they are flattened and usually more strained than they would appear in vivo. 
This difference in the orientation of the cells usually affects the cell processes 
including cell migration, multiplication, death, and expression of cellular 
products (7). Even with these characteristics in mind, most drug developers still 
use the conventional 2D cell culture systems to screen the drugs for cytotoxicity 
and effectiveness. 
 
Unlike in the 2D cell culture systems, the 3D culture systems form a spheroid 
of cells, with some receiving less nutrition and oxygen than others (8). The 
interactions of the cells with each other and with the matrix in the 3D setup more 
accurately mimic the in vivo conditions of the cells, and hence the cell 
morphology and other cell processes match those in the body (9). Various cell 
growth stages such as growth and proliferation, apoptosis, necrosis, and 
hypoxia can be easily mimicked in the spheroids (10). The spheroid centre is 
covered by layers of cells that make it hard to access an equal amount of 
oxygen, growth factors and nutrients and hence making the cells at the core 
remain quiescent (11). The outer layers of the cell remain viable because they 
have access to nutrients and oxygen. These characteristics of the cells in a 
spheroid therefore closely mimic tumour cells in the body (12). 
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Figure 1.1: Spheroid structure  
 
Likewise, the cellular processes in the 3D cell culture setup closely mimic the 
cell processes in the body (12). Taking cell proliferation as an example, the way 
it happens in the 2D is different from the cell proliferation in 3D. Some cells 
lines decline in the 3D setup while they continue growing in the 2D setup. 
Examples of such cells include colorectal cancer cell lines CRC. Other cells 
have been observed to multiply faster in the 3D setup than in the 2D cell culture 
systems such as breast cancer cells. The proliferation rate of the cell lines is 
also determined by the culture matrix in use (13). As much as some studies 
have shown that there is no significant difference between cells grown in the 
conventional cell culture system and the 3D setup, it is evident that the setup 
that closely mimics the in vivo scenario is the 3D culture system. Apart from the 
near identical mimic of the in vivo set up, 3D cultures also exhibit a reduced 
viability of cells and especially when the culture time is extended because of 
oxygen deficiency and nutrients and the accumulation of waste products at the 
spheroid core (14). 
The physiological and the physical characteristics of the cells in a 3D culture 
also clearly show that cell processes such as gene expression, protein, and 
receptor expression differ from that of cells in a 2D cell culture system (15). For 
example, in 3D culture system of ovarian cancer cells mRNA expression levels 
of the cell surface receptors and the protease MMP9 had considerably 
increased compared to cells in 2D culture (201). The cancer cells grown in 2D 
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and 3D cultures show considerable differences in the way the proteins and 
other cell compositions are expressed, and in the normal cell processes 
including migration and invasion as well as proliferation and angiogenesis (16). 
for example, the migration of primary human foreskin fibroblasts on BME in 2D 
structure is very efficient while in 3D structure using same material they are 
completely unable to migrate (202). As mentioned above, the massive 
difference in the cellular activities between cells in 2D culture and the 3D culture 
is mostly because of the orientation of the cells and the unequal access of the 
nutrients and oxygen in the medium (17). Around 30% of the genes are 
expressed differently when cultured in the 2D and the 3D culture systems which 
is a massive difference when it comes to conducting crucial tests (18). 
 
The genes responsible for limiting the proliferation and the growth of tissues 
are blocked in the 2D culture systems (19) as demonstrated in MCF10A breast 
cancer, a protein tyrosine phosphate, PTPRO had low to undetectable levels in 
2D cultures, Downregulation of PTPRO by RNA interference inhibited the 
proliferation block during morphogenesis (203). When growing cells in culture, 
the detached cells from the tissue of origin makes them lose their characteristic 
and gain new characteristics after being cultured in 2D. When they are taken 
back to the 3D culture systems, they regain their normal characteristics such 
as morphology and proliferation (19). Of consideration when growing cells in a 
3D culture is offering support for the translational and transcriptional processes 
that ensure that product profiles mimic the in vivo format (20). 
 
As mentioned above, the cell to cell contact and the cell to matrix contact is 
important in the determination of how the cells will grow and how their products 
will be expressed in 3D cell culture systems. The 3D model almost mimics the 
exact environment of the cells unlike the 2D cell culture (21). The 3D cell 
cultures, therefore, give a more closely related response to drug tests as would 
happen in the body and hence should be preferred for drug tests over the 2D 
culture systems (22). 
 
Research studies in cancer have shown that the cells and tumours in the 3D 
cell culture system tend to be more resistant to the cancer treatment drugs than 
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the 2D culture models. The activity and efficacy of the medicinal products in 3D 
culture is less than that in the 2D cultures (23). Drug interactions with the cells 
may require active interactions between cells and signalling from one product 
and cell to the other. This difference in the drug efficacy is therefore because 
of the difference in the cell to cell interactions, such as higher resistance to anti-
cancer drugs in 3D cell cultures and signalling compared to 2D culture systems.  
 
On top of that, the matrices involved also contributes to the way a cell makes 
its decisions on interacting with a drug (24) with one example showing that the 
presence of EGFR protein promotes drug resistance in a 3D model of breast 
cancer (204). The limited access to the cells in the core of the spheroid also 
contributes to cell survival as in cancer tumours and the reception of the drug 
into the cells (25). (Table 1.1) 
 
Cellular behavior 2D 3D 
Morphology Sheet–like flat Natural shape in spheroid 
 
Proliferation 
Regardless of cell types 
proliferation rate is faster 
than in vivo 
Depends on cell types 
proliferation rate could be faster 
or slower compared to 2D 
 
Exposure to drugs 
and nutrients 
 
Cells exposed to drugs 
equally 
 
Treatment agents may not be 
able to enter the spheroid core 
 
Cell cycle 
Mostly same cell cycle as 
equal exposure to nutrients 
Spheroids contain proliferative, 
hypoxic and necrotic cells 
Gene/protein 
expression 
Different expression levels 
compared to in vivo models 
More similar expression to vivo 
tissue origins 
Drug sensitivity Very effective treatment Less effective treatment 
Figure 1.2: The essential difference in cellular characteristics in 2D and 3D culture conditions (8). 
 
1.3. 3D models scaffold 
 
The formation of a 3D spheroid is determined by the matrix/scaffold in which 
the cells are grown. The cells are introduced into the medium which can be 
suspension medium and then allowed to attach to the polymerized 3D scaffold. 
The 3D matrices used in the 3D culture systems can either be synthetic or 
natural scaffold systems (26). Suitable 3D scaffolds must be used to mimic the 
spatial arrangement of cells in the body as well as provide the exact kind of 
support given to the cells in the body. Furthermore, the matrix must be 
cytocompatible to ensure that the cells grow and survive. The 3D cell culture 
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systems require the utilisation of suitable 3D scaffolds as in the body (27). 
These 3D scaffolds have been utilised in the processes of tissue engineering 
which requires complex cell interactions, and they have been adapted for the 
investigation of cell multiplication, development and the movement of cancer 
cells. This part of the introduction has been divided into two categories 
depending on the component of the scaffold: natural and synthetic scaffolds 
(28). 
 
Some of the 3D matrices for cancer models contain organic gels as their main 
component which acts as a substrate for the tumour cell growth. The organic 
hydrogels are weaker in terms of mechanical support than those that are 
synthetically generated. However, they manage to replicate the natural 
environment of a tumour. One of the most common organic compositions of the 
natural hydrogels is collagen which effectively mimics the ECM-like 
environment in vitro, as this protein constitutes the bulk of the ECM (29). 
Another component is laminin which can be used as a replacement for or 
additive to collagen. The advantage of using laminin or collagen in the 3D matrix 
is that it allows maximum cell survival because of its natural characteristics. 
Collagen and laminin also provide binding sites for cells, needed for interactions 
which promote proliferation and movement, such as the RDG sequence in 
laminin which provides a binding site for adhesion proteins “cell adhesion 
molecules, CAMs” which anchor cells to the matrix (205). The disadvantage is 
that they provide a weak mechanical support for the 3D cell culture spheroids. 
Collagen hydrogels has an advantage in that as the cells proliferate, they 
remodel it and hence increase the contact required for cell-cell interactions and 
the alignment of cells required to mimic in vivo environment (30). 
 
Reports show that some synthetic biological materials can mimic the features 
of the natural hydrogels while at the same time solve the support problem 
observed in the hydrogels to produce a more reliable 3D scaffold for cancer 
cells culture (31). On top of that, the synthetic matrices are biodegradable 
because they incorporate polymers such as polylactide, PGA, PLG, and PLGA. 
These polymers lead to the formation of different matrices such as mesh and 
fibres (32). They can, therefore, mimic the biological molecule structures 
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presented in the body. As mentioned above, these synthetic gels are more 
supportive mechanically, but they might have problems when it comes to cell 
adhesion to the polymers. In the bid to improve cell adhesion, the surfaces of 
the polymers are engineered (33). The process of mixing the scaffolds with 
some ECM compounds can also help increase the effectiveness of the 
synthetic scaffolds in cancer cell culture (34). The ability to engineer the 
scaffolds makes it easy to develop them into the preferred matrix without losing 
their ability to provide maximum mechanical support. The cell characteristics 
depend on the properties of the materials including their interaction with water 
and other external environments, the size of their pores and their chemistry 
(35). The process of engineering synthetic matrices to mimic in vivo structures 




 As mentioned above, collagen is one of the most utilised natural support 
systems for the 3D cell culture systems. Because collagen is the major 
component that makes up the connective tissue in the body, its ability to support 
the migration of the tumour cells in the external environment cannot be 
underestimated (37). Collagen gel is the most common to choose when it 
comes to more complex 3D assays because the protein stimulates the 
development of the endothelial cells which are important when it comes to the 
metastasis of the cancer cells (38). Collagen would be the most suitable support 
system for the 3D assays because cells proliferate unrestricted and its flexibility 
makes it easy to mimic the internal environment of the tumours (39). 
The fact that a considerable amount of oxygen and nutrients can pass through 
the collagen model into the core of the spheroid makes the hypoxia level of the 
cells in the core reduced (40). A Collagen construct has considerably large 
pores that make it possible for drugs that are of high molecular weight to diffuse 
and travel into and out of the matrix and hence making it easy to access the 
core of the tumour (41). The sources of collagen are natural substances that 
have a high amount of the product such as the bovine skin, the placenta, and 
the rat tail. The fact that collagen can interact with receptors such as integrins 
makes it even suitable because it is bound to support gene expression 
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naturally. In this case, the target is the genes that determine the production of 
metalloproteinases, the factors that are responsible for the degeneration of the 
extracellular matrix and those that stimulate and the invasion of the tumour 
cells. (42). 
 
1.5. Egg white 
 
Collagen and matrigel lack the ability to support a variety of cell interactions 
because they are designed to support only one type of cell. The egg white 
composition contained of protein, trace minerals, fatty material, vitamins, and 
glucose. The main three proteins included in the egg white composition that 
may potentially play a role in assisting the formation of cancer cells spheroids 
are Ovalbumin, Ovotransferrin and Ovomucoid. Since the development of the 
tumour incorporates the interactions between cancer cells and all the 
neighbouring cells, there is the need to find a matrix system that would support 
growth of the multicellular culture (43). Egg white is the best replacement when 
there is the need to synergise the growth of different types of cells all at once. 
The egg white can support the growth of cells from human, rat and mouse origin 
(43). This kind of matrix is essential when it comes to measuring the drug 
characteristics before and after angiogenesis. Apart from being effective, this 
method is also cost effective and yields reliable results for the assays (44). 
 
1.6. Crosslinked carboxymethylcellulose (CMC) 
 
Crosslinked carboxymethylcellulose (CMC) is another reliable hydrogel that is 
degradable biologically, non-toxic and non-mutagenic (45). Its main component 
is cellulose that has been modified to improve its qualities. Cellulose is a 
polymer found in plants such as cotton and wood. The engineered polymer 
makes it soluble in water by increasing the degree of substitution. The polymer 
is of high molecular weight with large pores and hence does not support the 
bioaccumulation of substances. The use of CMCs in clinical trials for breast 
implants has been investigated for the past two decades. The radio-
translucency of the CMC gel is higher than the silicone gel (45).   
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1.7. 3D models in drug discovery  
 
 Accessing the possible effects of a new compound, there is the need to 
conduct cell-based assays. The costs incurred during these processes is quite 
high and is estimated at 1.3$ billion. The number of drugs that pass the clinical 
trials is about 21%. Comparing the cost of the tests and the production of a 
marketable drugs, it is evident that the process is quite expensive (46). The use 
of 3D models is necessary because it reduces the costs incurred during trials 
in the clinical phase because it closely mimics the response of the body cells to 
the drugs and hence the failures in the clinical phase of drug testing are reduced 
(47). According to research studies, stronger drug resistance is caused by 
signals from the surrounding cells and the ECM impact on their decision-
making process (48). The limited access to the cells in the core of the spheroids 
make it easy to develop drug resistance in the 3D models. The variety of 3D 
models has attracted massive attention in drug screening assays. a number of 
3D models are inaccessible because of their high cost, time consumption and 
their lack of reproducibility (49). The 3D cell cultures have great potential in the 
future of drug discovery (50) (Table 1.2). 
 
Strengths  Weaknesses 
 
• ECM components increase 
cell-cell interaction 
• Cell morphology and function 
largely mimic what seen in 
vivo 
• Matrix could contain growth 
factor and protein in tumor 
condition. 
• Heterogeneous cell 
population are like tumour 
cells 
• Gene and protein expression 
levels like in vivo levels. 
• Models using different cell 
types to build multicellular 
systems. 




• Variability in biologically 
obtained matrices may lead 
to development of non-
producible results. 
• Cost more than 2D 
monolayer culture systems. 
• Some models produce 
spheroids of varying sizes 
which cause high variability in 
a well. 
• 3D models lack the 
vasculature which is 
significant for tumour growth 
rate and drug delivery. 
Figure 1.3: Advantages and disadvantages of 3D culture models for drug discovery applications 
(8). 
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1.8. Growth of tumors  
 
Tumours are a mass of cancer cells that grow under abnormal conditions 
enabling them to multiply bypassing apoptosis. The surrounding tissues are 
usually deprived of their nutrients by this mass of cells in its bid to survive. At 
the same time, the large amount of waste products overwhelms the surrounding 
healthy cells (51). The cancerous cells proliferate at a very high rate leading to 
the formation of the tumour which comprises of millions of cells. After a 
proportion of normal cells are deprived and die and hence fail to perform the 
normal cellular functions of the specific organ. The tumour cells continue 
occupying space and squeeze the normal ones to a diffusion-limited maximal 
size (52). The reason as to why tumour cells do not undergo apoptosis because 
of the low nutrient settings, but for their survival, they require less amounts of 
nutrients, oxygen and growth hormones than normal healthy cells. The tumour 
cells, furthermore, produce angiogenic factors that stimulate the growth of new 
blood vessels in a process referred to as angiogenesis (53). 
 
The process of angiogenesis is important in the expansion of a solid tumour 
and hence, this process is targeted by researchers to shed some light on the 
anti-cancer drugs resistance abilities of the tumour. It is one of the research 
areas that has sparked a lot of interest in cancer researchers because of its 
ability to generate a complex interaction of molecular processes (54). These 
molecules impact on the endothelial cells, how they multiply and how they 
invade the lining of the blood cells. One of the most important stimulatory 
molecules is the vascular endothelial growth factor (VEGF), and another one is 
basic fibroblast growth factor (BFGF) (55).  
 
The condition where oxygen requirements within a tissue drop to 5% of the 
normal physiological level called hypoxia often neighbouring areas of necrosis. 
Hypoxia outstrips the capability of the local vasculature to supply oxygen (53). 
In cancer tumours, hypoxia is related to poor projection of the diagnosis, 
resistance to treatment and increased probability of metastasis. The tumours 
are easily monitored using imaging techniques, for example, by positron 
emission tomography (56). To better understand hypoxia, 3D cell culture 
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models can help by mimicking the tissue hypoxia in vivo; image formation 
tumours can also be helpful. The high demand of oxygen in tissue and low 
vascular oxygen supply leads to hypoxia.  
 
Although many studies have been carried out in tumour vascular networks, 
tumour oxygen consumption is mainly ignored (25). The hypoxic tissues are 
more radio resistant than well-oxygenated tissues, and this has a significant 
effect on treatment as the cells in these hypoxic tissues do not respond well to 
either radio and chemotherapy (57). Hypoxia as well as necrotic conditions give 
the researchers the ability to develop therapy that is selective to only the tumour 
cells without having to invade the normal cells. This is done by targeting genes 
that are responsible for hypoxia such as those that express hypoxia-inducible 
factor 1 transcription. Hence these approaches could use this impediment and 




Figure 1.4: This shows tumour development from Stage 0 until stage IV and the process of 
determining how far a tumour has spread beyond its original location . (The cancer therapy 








1.9. Targeting studies 
 
 
Most of current cancer diagnostics and therapy usually include invasive 
procedures such as initial chemotherapy to reduce the tumours, and then 
surgical removal of the tumours if possible, and then more chemotherapy and 
radiation. The goal of the radiation and chemotherapy is to destroy the cancer 
cells as they are more likely to be harmed by the effects of the therapy due to 
their faster growth rate than normal healthy cells. For the past 20 years, the 
number of studies conducted to improve chemotherapy which has led to the 
development of the survival of patients has been on the rise. However, there is 
still a need for improvement. 
 
Recent research areas include carriers' improvement to allow complementary 
dosing methods, new therapeutic targets such as blood vessels fuelling tumour 
growth and specific targeted therapeutics (59). Research studies have shown 
patients are willing to embrace new treatment methods of cancer diagnosis and 
treatment.  
 
These new methods are aiming at ensuring that the patient leads a quality life 
and at the same time increasing survival rate (60). The level of effectiveness of 
these treatment methods, are determined by the ability of the drugs to target 
specific cancer cells and not the healthy cells.  (61). The ability of the drug to 
specifically target the cancer cells would leave the rest of the cells intact and 
hence improve the patient’s quality of life and life expectancy (62). The fact that 
can be used for more targeted treatment is that cancer cells tend to overexpress 
some their antigens on the cell surface (63). This makes it easy for the anti-
cancer drugs to target the specific tumour cell without causing harm to the 
normal cells. 
 
1.10. Targeting tumours using nanoparticles  
 
The use of nanoparticles to target cancer cells is an interesting prospect in the 
diagnosis and treatment of cancer. However, the dosage delivered to the site 
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is too low and hence may take long to diffuse the tumour. This is the main 
reason why transferring nanotechnology to human use has been a slow journey 
(64). The possibility of engineering nanoparticles that selectively detect and 
destroy cancer cells in the body remains an exciting concept which has led 
scientists to plan a myriad of different nanoparticle designs demonstrating 
unique physicochemical properties (size, shape and surface chemistry) and 
programmed with a multitude of biological and medical functions (65). 
 
When designing the ideal nanoparticles, their ability to deliver is of utmost 
importance. This is because the destruction of the tumour cannot happen if 
enough dosage of the drugs is not delivered to the site (66). The low delivery 
ability of the nanoparticles is the resistance it faces when travelling through the 
body including the shear, friction, protein adsorption and immune attacks (67). 
Nanoparticles that escape biological barriers could interact with the tumour 
tissue. The number of nanoparticles that can achieve this is stated as the 
nanoparticle delivery efficiency (68).  
 
Gold nanoparticles (AuNPs) are important components for biomedical 
purposes. AuNPs have been broadly used for diagnostics and have seen 
increasing use in the area of therapeutics. AuNPs have useful features such as 
size and shape related optoelectronic properties, large surface to volume ratio, 
excellent biocompatibility, and low toxicity. These properties make AuNPs an 
essential tool in bio-nanotechnology. Important physical properties of AuNPs 
include surface plasmon resonance (SPR) and the ability to quench 
fluorescence (219). 
 
Over the last two decades, fluorescent gold nanoclusters have been on the 
priority list of most researchers because of their outstanding photo stability 
characteristics (215, 69). Protein conjugated fluorescent gold nanoclusters 
(NCs) become more popular in the field of medical and nanotechnology 
because of their outstanding photo-stability characteristics such as unique 
advantages which include high sensitivity, cost effectiveness and diverse 
detection capabilities (70). Despite their great and promising future as 
innovative labelling agents, advance improvement of fluorescent gold 
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nanoclusters faces different challenges (71). Fluorescent gold nanoclusters 
(AuNCs) have a relatively low quantum yield (QY) compare to semiconductor 
QDs and natural dyes. Fluorescent gold nanoclusters produce unique multi-
functional nano probes for fluorescence imaging and detection (72). 
 
The interactions between proteins and fluorescent AuNCs have the significant 
impact on the biological behaviour of both proteins and fluorescent AuNCs (73). 
overall AuNCs as a biocompatible marker have amazing features for biological 
detection with good water-solubility, low toxicity, and high emission rates. The 
table below (1.3) is a summary of the recent advances in various biological 
applications of AuNCs in detection (74). They are still at an early stage, and 
further studies are required. Further development in design and synthesis of 
high-quality AuNCs lead to extensive applications in ultrasensitive molecular 
diagnostics and intercellular drug delivery in future.  
 
 
Figure 1.5: Biomedical applications of AuNCs (74). 
 
1.11. Tumor-specific targeting 
 
Current studies have shown that tumour specific targeting is a vital system in 
cancer therapeutics and diagnostics. When a drug is still attached to a tumour 
specific carrier, then it remains inactive until it reaches its destination (75). This 
is made possible because of the markers on the cancerous cells that are not 
present in the healthy cells. Since 1975, studies have first shown antibodies' 
AuNCs in 
biodetection
Detection of metal 
ions
11-MUA-capped AuNCs used for 




Glutathione-stabilized AuNCs are 
capable of  GST-tagged proteins 
detection from cell lysates
Detection of small 
biomolecules
11-MUA-AuNCs based on luminosence 
for quatntitaive determination of H2O2
Detection of 
nucleic acids
Flourencence AuNCs use in nucleic 
acids delivery
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ability to bind to specific tumour antigens. However, it took about 20 years to 
develop the antibodies into compounds that can fight cancer (76).  In all cancer 
cells, targeted antigens should be expressed but not on host cells. The FDA 
has approved many of targeted cancer therapies using antibodies for various 
cancer types, such as anti-epidermal growth factor receptor antibodies (anti-
EGFR cetuximab) and anti-HER2 antibody (Herceptin) (77).  
 
Studies have shown that these therapeutic methods using antibodies directed 
to cancer targets will lead the market. For more efficient and less invasive 
cancer treatments, these antibodies will be used heavily as therapeutic agents 
or even carriers for drug transport processes (78). It is important to generate 
targeted treatment methods that alter the target in a way that inhibits its ability 
to promote the survival of cancer cells. The targeted therapy could prevent the 
targets from attachment to a receptor that they routinely activate, among other 
potential tools or reduce the target activity (79).  
 
As it has been mentioned earlier, most of the targeted cancer therapies use 
antibodies. Antibodies are large, and they, therefore, cannot enter the cells. 
Hence, they are used only to target the surface of the cell (80). Typically, the 
antibodies are created by injecting the antigen to be targeted into a rat. The 
rat's immune system in the quest to fight the antigen develops antibodies 
against it. The antibodies are then tested for their selectivity in combating the 
antigens (81).  
 
The next stage for the tested antibodies is to be used in humans a process 
referred to as "humanising." Humanising is essential for blocking the human 
immunity from demolishing the antibody and recognising it as "foreign" before 
it has a chance to bind to the target. In the Humanization procedure, a 
reasonable number of human antibodies are replaced with a consistent portion 
of mouse antibodies. Finally, small-molecule compounds are not usually 
recognised as foreign by the host. Hence, humanization is not an issue for that 
(82). Many appropriate cancer targeted therapies can be used such as signal 
transduction inhibitors, hormone therapies, gene expression, modulators, 
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apoptosis inducers, angiogenesis inhibitors, immunotherapies, and toxin 







when the cell has received a signal, the signal is transferred to 
the cell through a series of biochemical reactions that eventually 
provide the relevant responses. 
 
Hormone therapies 
The body interferes with the hormones action and stops from 
providing the hormones.  
 
Gene expression 
Proteins perform a role in regulating gene expression, by 
changing proteins function. 
 
Apoptosis inducers 





By stop the angiogenesis to tumours inhibits new blood vessels 
growth interfere with vascular endothelial growth 
factor (VEGF) action. 
 
Immunotherapies 
The recognition of specific antibodies on the cancer cells 
surface, to destroy cancer cells by trigger the immune system. 
Toxin delivery 
molecules 
The antibodies that deliver toxic molecules may cause the 
cancer cells die. 
Figure 1.6:  Different cancer targeted therapies (83). 
 
There are other cancer therapies such as cancer vaccines, and gene therapy 
that interfere with the growth of specific cancer cells and antibodies as targeted 
therapies to specific cancer cell markers as shown in table 1.5 (84). 
 
Antigen types Antigen examples Tumor types 
Glycoproteins EpCAM Breast & Colon 
Glycoproteins CEA Breast & Colon 
Glycoproteins gpA33 Colon 
Glycoproteins Mucins Breast & Colon 
Glycoproteins TAG-72 Breast & Colon 
Carbohydrates Lewis-Y2 Breast & Colon 
Growth factor EGFR Breast & Colon 
Growth factor HER2 Breast & Colon 
Growth factor ErbB3 Breast & Colon 
Growth factor c-MET Breast 
Growth factor IGF1R Breast 
Growth factor EphA3 Colon 
Growth factor TRAIL-R1, TRAIL-R2 Colon 
Stromal & extracellular matrix antigen FAP Breast & Colon 
Stromal & extracellular matrix antigen Tenascin Breast 






1.12. Calreticulin (CRT) 
 
The endoplasmic reticulum (ER) is a network of membrane-enclosed tubules 
and sacs that extends from the nuclear membrane throughout the cytoplasm. 
The whole endoplasmic reticulum is surrounded by a continuous membrane 
and is the largest organelle of most eukaryotic cells.  Calreticulin (CRT) is a 
compound that is predominantly situated in the ER (86). CRT is also found in 
the nucleus, which means that it aids in the process of transcription regulation. 
Structural predictions show that the protein consists the N, P, and C-domain 
(87). CRT has got two main functions inside the ER; regulation and moving 
calcium ions. CRT can, therefore, act a target for the regulation of gene 
expression (88). The correlation between expression level of CRT and 
tumorigenesis has been widely studied in cancer research (89). The level of 
expression of CRT leads to different clinical outcomes. By increasing the levels 
of CRT, cancer development process would be damaged. When CRT is 
expressed in high levels, it can help develop a treatment for cancer (90). The 
interaction with integrins is a mediation tool that can be used for this process 
(91). 
 
1.13. Imaging of spheroids  
 
The 3D spheroids have a high potential for use in cancer therapeutics in the 
future because they mimic the behaviour of tumour in vivo better than that seen 
in 2D culture systems (92). The imaging and analysis process of the 3D 
spheroids experience some challenges as documented in the table 1.6 below. 
 
3D spheroids limitations in imaging and analyzing 
Find the spheroid and focusing on that in every well so it can be imaged in a single 
field-of-view. 
To confirm dye penetration and prevent disturbing the spheroid location the most 
effective compound and staining treatment required. 
To get the representative images throughout the 3D matrices, background signal 
from above and below the imaging level or decreasing out-of-focus. 
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To analyze the images to produce meaningful result. 
Figure 1.8: limitations in imaging of 3D spheroids (92). 
There are some different biological records from spheroid assays that have 
been explained. High-contrast imaging techniques have been proven as 
promising methods for characterizing the effects of chemical compounds on 
spheroids. Recently, spheroid formation in low-attachment plates has become 
popular as the technique is suitable for high-content imaging (49). Imaging has 
advantages over other analytic procedures, such as plate reader-based 
fluorescence or luminescence, where no spheroids interference is required, 
and multiple biological records are possible, as indicated below (93). 
 
The viability dyes, apoptosis dyes, DNA-binding dyes and fluorescence 
markers can be all used in fluorescence imaging. For example, cancer cells can 
be transfected with fluorescent proteins at the early stage before spheroid 
formation to allow detection of changes in spheroid size or intensity by 
fluorescence (92). This technique can be prolonged to more complex 
multicellular models that express fluorescent marker groups. Transmitted light 
(TL) imaging can be used to determine the spheroid size and, same density 
level (92). Normally, the large magnification index makes it easy to view a single 
cell and hence the collection of information of the spheroid is easy. Low-
magnification is only used when the whole spheroid needs to be observed (94). 
 
The confocal imaging system is another imaging technique. There are three 
tactics to be used for confocal imaging technique to achieve out-of-focus plane 
removal (95). 1) by using a blocked pin-hole gap in a conjugate focal plane to 
the specimen so that light transmitted away from the point in the sample being 
illuminated is physically blocked from reaching the detector 2) by illuminating a 
single point of the specimen at any one time with a focused beam. And 3) By 
using software deconvolution to use mathematical calculation to estimate the 
effects of out of focus plane for any plane and hence removing these distortions. 
In most biomedical applications, gold particles used for fluorescence imaging, 
however, can be used in immuno-gold labelling (96). Although in this reported 
growth, morphology hypoxia and targeting of the 3D spheroids were checked 
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at different time points for any changes in the area, volume and form were 




The aim of this thesis was to develop a 3D culture matrix, which allows for the 
growth and subsequent harvesting of cancer cell spheroids for nanocluster 
investigations. 
The specific objectives are: 
1. Combining low temperature melting agar with collagen or egg white 
(albumin) to generate biomimetic 3D matrices for cultivating cancer cell 
spheroids was carried out.  
2. Novel natural macromolecule based carboxymethyl cellulose (CMC) in 
combination with gelatine as 3D matrices was also developed for 
spheroid formation. 
3. Formed spheroids were harvested from all matrices and used for 
targeting with fluorescent gold (AuNCs) for microscopy detection of a 
novel cancer marker. 
4. Harvested spheroids were also used for co-cultivation with endothelial 
cells in extravasation studies.   
5. Mature spheroids were examined for the detection of hypoxia within the 
spheroids 
6. Water soluble fluorescent gold nanoclusters AuNCs were synthesized 

































2. Methods and Materials: 
 
2.1. Routine cell culture 
 
The colorectal cancer cell line (HT29) a breast cancer cell line (MCF7) and the 
human umbilical vein endothelial cell line HUVECs have been used in this body 
of work (all purchased from the European Collection of Cell Cultures, ECACC, 
Salisbury, UK and Sigma-Aldritch, Dorset, UK). The cancer cell lines were 
grown in Dulbecco’s Modified Eagle Medium (DMEM) with high glucose/L, 
GlutaMAX™-I, without phenol red, without HEPES and pyridoxine HCl (Sigma- 
Aldrich, D6046) supplemented with 10% Foetal Calf Serum (FCS, 5129, First 
Link UK Ltd, Birmingham, UK) and 1% Penicillin/Streptomycin with 10,000 
units’ penicillin and 10 mg streptomycin per mL in 0.9% NaCl, sterile-filtered, 
(P/S, GIBCO, Invitrogen, Paisley, UK). HUVECs were grown in Endothelial 
Growth Medium (PromoCell Heidelberg, Germany) with 1% Pen strep.  All the 
cells were handled aseptically and cultured routinely as 2D monolayers in a 
humidified atmosphere with 5% CO2/air at 37°C in a Forma Scientific CO2 
Incubator. Passaging for propagation and viable freezing (liquid Nitrogen 
stocks) was carried out enzymatically (1mg/ml Trypsin in EDTA/PBS, GIBCO) 
at between 75-90% confluence. Cells were purchased in passage 5. Cells were 
used within 30 passages, at which time more cells were taken out of stock. 
Regularly, cells were feed every three days. Routine plasticware was 
purchased from VWR (Leicestershire, UK) and Greiner Bio One (Stonehouse, 
UK) 
 
2.2. Optimum density on 2D  
 
For 2D studies, cells (HT29, MCF7) were seeded in 96 well plates in the order 
of 10x103 cells/ml up to 2x105 cells/ml and after 24 h incubation at 37o C the 
metabolic activity was checked using alamarBlue. The alamarBlue assay is 
designed to measure quantitatively the proliferation of both cell lines (HT29, 
MCF7). The alamarBlue Assay incorporates a fluorometric/colorimetric growth 
indicator based on detection of metabolic activity. Specifically, the system 
incorporates an oxidation-reduction (REDOX) indicator that both fluoresces and 
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changes colour in response to chemical reduction of growth medium resulting 
from cell growth. The standard curve results show the optimum cell density to 
be used in 2D (concentrations were chosen from the linear part of the curve). 
 
2.3. 3D in vitro model with two types of matrices (Agar & 
Collagen) (Agar & Egg white) 
 
The following matrix components were used: Low melting agar (Sigma, UK), 
collagen type I with 2.05 % protein concentration (First Link, UK); eggs (MS 
Free range), which were surface sterilized by wiping with 70% ethanol under 
sterile conditions. The egg white was separated from the egg yolk by puncturing 
the shell at one end and transferring into sterilized universal containers (Greiner 
Bio One) and subsequently frozen down (-20oC) until needed.  
 
To create the 3D, model the following steps were taken. The low melting agar, 
type I collagen and egg white were all maintained in a water bath at 40o C. For 
the experiments, 3 ml of type I collagen or 3 ml of egg white and 3 ml of low 
melting agar (1:1) were mixed; and equal volumes of fully supplemented DMEM 
added.  
 
The final solution was dispersed into wells of ultra-low binding plates 12-well, 
or 24-well depending on experimental protocols (purchased from Sciencell, 
Carlsbad, USA). At the same time, sterilized individual Glass beads (5mm 
diameter, Sigma) were placed in the middle of the 3D mixture, just before 
starting to cool to form a gel while in the sterile tissue culture cabinet. After 10 
min of gel formation the glass beads were removed to create a well within the 
3D construct, which was then filled with 0.1 ml of cancer cell suspension 
containing optimum number of cells (HT29, MCF7) and let it to settle in the 
tissue culture cabinet for 20 min and topped up with fully supplemented medium 




2.4. Optimum density in 3D A/E and A/C 
 
For 3D studies, cells (HT29, MCF7) were seeded in prepared A/E and A/C 3D 
matrices in order from 25x103, 50x103, 75x103,100x103 cells/ml and incubated 
at 37o C. Afterwards the cell metabolic activity was measured on specific time 
points (Day 1,4,7 and 10) (Over 3 independent experiments). At each time point 
cell medium was removed and 300 l of 10% alamarBlue reagent was added 
to each well, and the plate was incubated at 37°C for approximately 5 h 
(Incubation time varied between 4 h up to 8 h) to allow cells to convert resazurin 
to resorufin and produce their characteristic colour. After the incubation time 
the resultant absorbance signal was measured (Excitation 530, Emission 620). 
Metabolic activity results showed 75x103 cells/ml is the optimum density to use 
in 3D A/E and A/C models.  
 
2.5. Preparation of novel CMC matrix for 3D model 
 
Sodium Carboxymethylcellulose and Bovine Gelatine comprised the new 
matrix (CMC mixture). 4g of CMC were dissolved by adding gradually to a 
stirring container in 100 ml of water and the mixture was boiled. After cooling 
and standing in the fridge overnight to complete dissolution, 1g of gelatine was 
weighed and added to the CMC solution and mixed thoroughly. To sterilize, the 
mixture autoclaved at 121o C for 25 min and allowed to cool. The mixture was 
now considered (x2), so to use it was diluted 1:2 with growth medium and mixed 
gently.  
2.6. 3D CMC water swelling capability 
 
The 24-well Ultra Low Binding plate was weighted before and after transferring 
1 ml of the CMC mixture into the well. By using freeze-drying which is 
a dehydration process, CMC mixture froze and then reducing the 
surrounding pressure to allow the frozen water in the CMC mixture 
to sublimate directly from the solid phase to the gas phase. Eventually freeze-
dried CMC mixture was weighted. This shows the weight of the plate contains 
1 ml of CMC mixture before and after dehydration process. 
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2.7. Viscosity properties of Carboxymethycellulose and 
CMC+gelatine 
 
Another physical property is viscosity of CMC; therefore, a viscometer was used 
to measure the viscosity of the fluid. 1 ml of CMC solution was added and the 
viscosity level of that compared with the viscosity of CMC+gelatine (CMC 
mixture). It is important when applying a sample that the correct amount is used. 
Over filling or under filling will result in errors in your data. The total test is 
carried out at room temperature. Many different measuring systems can be 
used on the rheometer.  
To check the viscosity level of CMC mixture, the Cone/plate measuring system 
is recommended. The advantages of using this system are easy to clean, 
suitable sample position, small sample volume needed, shear rate constant 
across the sample, and finally high shear rates possible with small angle Cone. 
Cone/plate measuring system contains of a rotating upper Cone and a fixed 
lower plate with CMC mixture contained between them. Since the shear stress 
is constant (within 0.3%) with radial position for Cones with a small Cone angle, 
the viscosity of CMC mixture can be analysed directly from the experimental 
torque/speed relation. For Cone/plate measuring system, it is normally easier 
to slightly over fill and then trim off any excess sample after bringing the upper 
and lower measuring systems together. It is important to clean the rheometer 
after use. Samples left behind may damage the surfaces of the measuring 
systems.     
2.8. Optimum cell density in 3D CMC+gelatine  
 
To check the optimum density in 3D CMC+gelatine matrix, cancer cells (HT29, 
MCF7) were dispersed into prepared CMC+gelatine 3D matrices in 24-well 
ultra-low binding plate in order from 25x103, 50x103, 100x103, 150x103 cells/ml 
and incubated at 37o C. Afterwards cells metabolic activity was measured on 
specific time points (Day 1,4,7 and 10) (Over 3 independent experiments). At 
each time point cell medium was removed and 300 l of 10% alamarBlue 
reagent was added to each well, and the plate was incubated at 37°C for 
approximately 5 h (Incubation time varied between 4 h up to 8 h) to allow cells 
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to convert resazurin to resorufin and produce the characteristic colour. After the 
incubation time the resultant absorbance signal was measured (Excitation 530, 
Emission 620). The final results showed 100x103 cells/ml is the optimum 
density to be used in CMC+gelatine 3D model. 
 
2.9. 3D in vitro model with CMC+gelatine matrix 
 
1 ml of the CMC mixture (CMC+gelatine) was transferred into each well of a 
24-well ultra-low binding plate and the plate was placed into the fridge for 10 
min to set the matrix. Same optimum density used in previous 3D model, hence 
100x103 cells (HT29, MCF7) and HUVECs were dispersed into the matrix and 
after 10 min the cells settled within the matrix, the 3D CMC mixture was topped 
with DMEM.  
2.10. Live/Dead Assay - Propidium Iodide and FDA  
 
Fluorescence-based live-dead assays can be used to evaluate the viability of 
mammalian cells. For this technique, the two chemical dyes used Fluorescein 
diacetate (Sigma-Aldrich Company. LLC, C-7521). FDA stock solution which 
was prepared by dissolving 5 mg of FDA in 1 ml acetone (stock solution kept at 
-20 °C). Propidium iodide (for example: Sigma-Aldrich Co. LLC, P4170). PI 
stock solution was prepared by dissolving 2 mg of PI in 1 ml PBS (stock solution 
kept at 4 °C). Simultaneous use of two fluorescent dyes allows a two-colour 
discrimination of the population of living cells from the dead-cell population. the 
current staining protocol used fluorescein diacetate (FDA) and propidium iodide 
(PI), which stain viable cells and dead cells, respectively.  
The staining protocol is applicable to grown spheroids on CMC 3D matrix. Non-
fluorescent FDA taken up by (HT29, MCF7) cancer spheroids and convert into 
the green fluorescent metabolite fluorescein. The measured signal acts as 
marker for viable cells, as the conversion is esterase dependent. In contrast, 
the nuclei staining dye PI cannot pass through a viable cell membrane. It 
reaches the nucleus of cancer cells by passing through disordered areas of 
dead cancer cell membranes and intercalates with the DNA double helix of the 
cancer cell. Hence, dead cells stain red. The staining solution mixture of 
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Fluorescein diacetate and Propidium iodide (PI) was freshly prepared to be 
used within 2 h. It was kept protected from light and placed it at 4°C when not 
needed. Spheroids were collected from their CMC 3D matrices using 
centrifugation with 800 rpm after 5 min. Afterwards the supernatant was 
removed, and 1 ml staining solution added to the spheroids, then the next step 
was the incubation of each sample at room temperature for 4 to 5 min in the 
dark. The staining solution was removed using same procedure centrifugation 
with 800 rpm after 5 min. The spheroids were washed by PBS and centrifuged 
with 800 rpm after 5 min. Eventually PBS or medium without FCS was added 
to sample, and the sample analysed by fluorescent microscopy (inverted 
fluorescent microscope with filter sets for Texas Red and FITC).  
2.11. Hypoxia assay - to measure oxygen (O2) levels 
 
Image-iT Hypoxia Reagent is a novel fluorogenic compound for measuring 
hypoxia in live cells. Therefore, hypoxia level of HT29 and MCF7 spheroids 
were checked through specific time points.  It is non-fluorescent when live cells 
are in an environment with normal oxygen concentrations and becomes 
fluorescent when oxygen levels are decreased. Both cell lines were seeded into 
the CMC 3D matrices and hypoxia level were checked using Image-iT Hypoxia 
reagent. The reagent is fluorogenic when atmospheric oxygen levels are less 
than 5%. Image-iT Hypoxia Reagent is provided as a lyophilized powder. To 
make 1 mM stock solution, the lyophilized powder was dissolved in 1.40 mL of 
DMSO. The reagent was added to the cells at a final concentration of 5–10 μM 
and incubated for 15 to 30 min. cells were imaged under the fluorescence 
microscope with excitation/emission of 490/610 nm. Spheroids oxygen level 
with less than 5% indicate higher red fluorescence therefore, there are more 
hypoxic.   
2.12. Harvesting spheroids from 3D matrices 
 
Well-structure formed spheroids in A/E, A/C and CMC matrices are 
harvestable. At day 10 spheroids grown in all types of matrices. However, to 
use spheroids for further experiments the CMC matrix is less elaborate to use. 
Hence, grown spheroids collected from the 3D CMC matrix and transfer into 
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the universal using 5 min low speed, gentle centrifugation process 800 rpm, 
and when supernatant discarded, the spheroids are ready to be harvested 
again into the fresh CMC matrix. 
2.13. Synthesis of AuNCs 
 
Fluorescent AuNCs were made following a one pot synthesis method, by 
reducing gold salt with minimum amount of DMF in the presence of MSA: 
specifically, chemicals were introduced consecutively, beginning with MSA and 
then DMF in aqueous solution with strong mixing. The formation of a light brown 
colour is an indication of the production of ultra-small non-fluorescent NCs. The 
exposure of the prepared mixture to hydrothermal heating at 121o for a period 
of 25 min followed by a cooling phase resulted in the production of NIR-emitting 
NCs. Importantly, no fluorescence was detected prior to the heating process 
showing that exposure of the mixture to a high temperature as well as the 
gradual reduction by DMF contained in the AuNCs capped with MSA leads to 
luminescence of the nanoparticles.  
 
The absorption and emission of MSA–AuNCs checked by spectroscopy. 
Therefore, toxicity and targeting fluorescent (800 nm) gold nanoclusters 
(AuNCs) were manufactured in house as above, TEM imaging of MSA–AuNCs 
also indicated an average core diameter of 2nm. These were further conjugated 
to antibodies against Calreticulin (CRT), a potential cancer biomarker or 
antibodies against epidermal growth factor (EGFR). The chemistry, 
manufacture and characterisation of the antibodies against CRT are not 
presented in detail in this report, as they had been previously raised for another 
study (kindly provided by Dr. B Ramesh, UCL Division of Surgery and 
Interventional Science). Antibodies against EGFR were purchased 
commercially (Abcam Company, UK). 
 
2.14. AuNCs Conjugation to Anti-Calruticulin 
 
Fluorescent AuNCs solution was diluted with equal volume of cold 100% 
ethanol and centrifuged at 4000 rpm for 30 min. The precipitated AuNCs were 
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vacuum dried to obtain as a powder. The precipitated dried NCs 
(approximately, 1 mg) were re-suspended in 1 mL phosphate buffer saline 
(PBS) and centrifuged at 4000 rpm for approximately 10 to 15 min. The 
obtained coated NCs (1 mL) solution was conjugated to anti-CRT using EDC 
as an acylating agent together with NHS. Briefly, 200 L Au/MSA solution (1 
mg/mL) was mixed with 200 l EDC (1 mg/mL) and 200 L NHS (1 mg/mL) in 
PBS for 30 min at room temperature. 100 L of CRT solution (2 mg/mL) was 
added to the mixture and mixed for 2 h at room temperature. Double 
conjugation was carried out by repeating the above procedure but only with the 
synthetic CRT peptide to fully saturate the carboxylate functional sites.  To 
separate the conjugation reagents, the mixture was diluted with ethanol (1:2 
ratio) to precipitate the NCs-CRT and dried at room temperature. The purified 
NCs-(Anti-CRT) defined as Au/MSA conjugated to (Anti-CRT) was collected 
and stored at 4º C until further use. The sample was further characterized by 
NIR fluorescence and TEM microscopy.  
 
2.15. Immuno-chemiluminescence detection for AuNCs-Anti-
CRT 
 
Dot blots were carried out for confirmation of conjugation of Anti-CRT 
antibodies and calreticulin synthetic peptide to gold nanoclusters. 5ul of   1:1000 
dilution of anti-CRT antibodies conjugated to AuNCs (1mg/ml) in water was 
marked onto aqueous equilibrated PVDF membrane and allowed to dry at room 
temperature. On drying the membrane was washed gently in PBS with 0.05% 
Tween 20 (PBS/T; pH 7.4) and was incubated overnight at room temperature 
in 2% BSA with 0.005% sodium azide to block any remaining binding spots on 
the membrane. For the detection of the marked AuNCs-anti-CRT the 
membrane was washed for 5 min (3x) with PBS and then exposed to anti-rabbit 
conjugated to horse radish peroxidase (HRP). After 1 hour incubation rabbit 
AuNCs-anti-CRT bind together. The strip was washed in PBS for 5 min (5x) 
and used for chemiluminescence detection of the spots to check conjugation.   
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2.16. AUNCs conjugation to Anti-EGFR 
 
The fluorescent AuNCs solution was diluted with 1 volume of cold 100% ethanol 
and centrifuged at 4000 rpm for about 10 min. Fluorescent AuNCs were 
conjugated to EGFR antibody from (Abcam Company, UK) using the N-(3-
dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC) coupling 
reaction. Based on the supplier’s information of the EGFR antibody titer 
(1:2500), after conjugation, a titer of (1:2500) was found to be suitable to use 
throughout the experiments.  
Briefly 100ul of Fluorescent AuNCs solution (about 200ug/ml, assessed by dry 
weight) was mixed with 100ul of Anti-Anti-EGFR. 200ug of EDC was then 
added to the mixture and mixed for 2 h. Due to the addition Anti-Anti-EGFR, 
Fluorescent AuNCs conjugates are larger than non-conjugated AuNCs and can 
be separated by centrifugal filter with a cut off 3 kD membrane. 
 
2.17. Immuno-chemiluminescence detection for AuNCs-Anti-
EGFR 
 
Dot blots were carried out for confirmation of conjugation of Anti-EGFR 
antibodies by colleague in another report. 5ul of   1:1000 dilution of anti-EGFR 
antibodies conjugated to AuNCs (1mg/ml) in water was marked onto aqueous 
equilibrated PVDF membrane and allowed to dry at room temperature. On 
drying the membrane was washed gently in PBS with 0.05% Tween 20 (PBS/T; 
pH 7.4) and was incubated overnight at room temperature in 2% BSA with 
0.005% sodium azide to block any remaining binding spots on the membrane. 
For the detection of the marked AuNCs-anti-EGFR the membrane was washed 
for 5 min (3x) with PBS and then exposed to anti-rabbit conjugated to horse 
radish peroxidase (HRP). After 1 hour incubation rabbit AuNCs-anti-EGFR bind 
together. The strip was washed in PBS for 5 min (5x) and used for 
chemiluminescence detection of the spots to check conjugation.   
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2.18. Toxicity studies in 2D cultured cells 
 
For toxicity studies, cancer cells (HT29, MCF7) and endothelial cells (HUVECs) 
were seeded into 24 well plates (40x103 per well) for 48 h, and then exposed 
to different concentrations of AuNCs or constituent compounds. After 24 h, 
metabolic activity (as a measure of proliferation) was measured, using the 
alamarBlue assay. Briefly, 300 alamarBlue the reagents were added to each 
well, the plates were incubated at 37°C approximately 4 h to allow cells to 
convert resazurin to resorufin, and the resultant absorbance signal was 
measured (Excitation 530, Emission 620). Results are presented by plotting the 
absorbance signal versus concentration of each test compound. 
 
2.19. Targeting studies in 2D fixed cancer cells 
 
For primary targeting studies, 2D culture systems are optimal. The cancer cells 
(HT29, MCF7) and HUVECs were seeded in 24 wells plate (4x103 per well) 
incubated for 24 h and then fixed using Paraformaldehyde solution (4% in PBS). 
The fixed cells were rinsed in PBS and incubated with 100 µl of the 100 µl/ml 
conjugated AuNCs-Anti-CRT for 30 min at 37C and washed with PBS to 
remove all excess off. To check the specificity of targeting the cancer cells and 
endothelial cells were seeded in 24 well plate (40x103 per well) incubated for 
24 h and then fixed using Paraformaldehyde solution (4% in PBS). The fixed 
cells were washed in PBS and incubated with 100 µl of the 100 µl/ml non-
conjugated AuNCs for 24 h at 37C and washed with PBS to remove all non-
specific bindings. 
 
2.20. Targeting studies in 2D live cultured cells 
 
For primary targeting studies, 2D culture systems are optimal. The cancer cells 
(HT29, MCF7) and HUVECs were seeded in 24 wells plate (40x103 per well) 
incubated for 24 h. Cells were incubated with 100 µl of the 100 µl/ml conjugated 
AuNCs-Anti-CRT for 30 min at 37C and then cells were washed with PBS to 
remove all non-specific bindings. For the control cancer cells and endothelial 
cells were seeded in 24 well plate (40x103 per well) incubated for 24 h and then 
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with 100 µl of the 100 µl/ml non-conjugated AuNCs for 24 h at 37C and washed 
with PBS to remove excess off.  
 
2.21. Targeting studies in 3D fixed spheroids 
 
At day 10 when spheroids well-formed, spheroids were harvested using low 
speed, gentle centrifugation at 800 rpm for 5 min. Spheroids were fixed using 
Paraformaldehyde solution (4% in PBS). The fixed spheroids were rinsed in 
PBS and 100 µl of the 100 µl conjugated AuNCs-CRT applied. While for the 
controls, spheroids were fixed without applying any substance. After 1 hour 
both spheroids samples were washed using PBS and imaged by fluorescence 
microscopy.  
2.22. Nucleic acid stain studies in 3D fixed spheroids 
 
 At day 10 when spheroids well-formed, spheroids were harvested using low 
speed, gentle centrifugation at 800 rpm for 5 min. Spheroids were fixed using 
Paraformaldehyde solution (4% in PBS). DAPI is a blue fluorescent nucleic acid 
stain that specially stains double-stranded DNA. It attaches to AT clusters in 
the DNA in fixed spheroids. DAPI binds to dsDNA and produce an approximate 
fluorescence enhancement. Fixed spheroids were imaged using florescence 
imaging. The fluorescence is directly proportional to the amount of DNA 
present, with emission maximum at 460nm. Although cations do considerably 
reduce its (blue) fluorescence, the fluorescence is unaffected over different pH 
range.  
2.23. HUVECs grown on filter inserts  
 
Crystal Violet assists in colorimetric measurement of cell viability. It has also 
been used for the staining of cells to study cell migration and invasion. 
Therefore, HUVECs were seeded on filter insert (0.45μm), after 48 h 
incubation, HUVECs were theoretically attached to the filter insert. However, to 
see the existence and attachment of HUVECs on membrane, HUVECs were 
stained using Crystal Violet staining solution. 100 ml of this staining solution 
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were applied onto the surface of filter insert and then briefly washed using PBS. 
Finally, the HUVECs imaged by fluorescence microscopy.  
2.24. Specific targeting of grown 3D spheroids within the 
CMC+gelatine matrix 
 
HUVECs were seeded on filter insert, after 48 h cells become confluent enough 
and cover the surface of filter inserts (0.45μm). At day 10 when spheroids were 
well-formed on CMC matrix, they were harvested using low speed, gentle 
centrifugation at 800 rpm for 5 min. Grown spheroids transferred into 6 well 
ultra-low binding plates within the new CMC 3D matrix. HUVECS seeded filter 
inserts placed on top of the 3D matrix, as a membrane and then 200 µl of 100 
µl/ml conjugated AuNCs-Anti-CRT were applied to the membrane surface. For 
the control sample, empty filter inserts placed on top of the live spheroids and 
then 200 µl of 100 µl/ml conjugated AuNCs-Anti-CRT were applied onto the 
empty filter inserts.  
This will lead to have better understanding of HUVECs behaviour that may 
affects targeting of grown spheroids. Afterwards spheroids were imaged in both 
conditions using fluorescence imaging microscopy and compared fluorescence 
intensity of them together, this will indicate any possible effects of HUVECs. To 
check the specificity of targeting in CMC 3D matrix, HUVECs were seeded on 
filter insert, after 48 h cells become confluent enough and cover the surface of 
filter inserts (0.45μm). The filter inserts placed on top of the 3D matrix without 
any spheroids, as a membrane and then 200 µl of 100 µl/ml conjugated AuNCs-
Anti-CRT were applied onto empty 3D matrix. For the control 200 µl of the 100 
µl/ml of conjugated AuNCs-Anti-CRT were applied onto the empty filter insert 
placed on top of the 3D matrix with no spheroids. Finally, both conditions were 


























3. Results  
 
The aim of this chapter is to investigate and characterize the growth of cancer 
cell lines in different 3D matrix conditions, natural and synthetic. Two cancer 
types took forward: 1) colorectal cancer and 2) breast cancer; endothelial cells 
were also used, as described below. 
 
 
3.1. Basic growth characteristics of cell lines in 2D cell 
culture 
 
3.1.1. Growth of colorectal cancer cells 
 
The cancer cell line was used as an exemplar for colorectal cancer was HT29.  
In their routine media, their doubling time of cells is 3 to 4 days. HT29 are 
tumorigenic in vivo models, and they look different at high densities in 2D cell 
culture. However, the ATCC picture could be considered as the regular 
appearance, although, there is no "standard appearance." Their morphology 
under the current growth conditions appears “epithelial,” and as they grow, they 
tend to arrange themselves in somewhat glandular structures (Figure 3.1). 
 
 
Figure 3.1. Human colon adenocarcinoma cell (line HT29) were seeded in T75 flask and at day 3 
imaged using light microscopy in 10x magnification 
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3.1.2. Growth of breast cancer cells 
 
The cancer cell line used as an example for breast cancer was MCF7.  MCF7 
is the acronym of Michigan Cancer Foundation-7, referring to the institute in 
Detroit where the cell line was established in 1973. MCF-7 cells are useful for 
in vitro breast cancer studies because the cell line has retained several ideal 
characteristics to the mammary epithelium. Their morphology in 2D cell culture 
appeared to retain epithelial characteristics and like HT29 they sometimes try 
to form glandular aggregates (3.2).  
 
 
Figure 3.2. Michigan Cancer Foundation-7cell (line MCF7) were seeded in T75 flask and at day 3 
imaged using light microscopy in 10x magnification. 
 
 
3.1.3. Growth of endothelial cells (ECs) 
 
A non-cancer, non-epithelial cell line was also used of endothelial cells to 
represent normal cells and to be able to incorporate later in complex 3D models 
as a cell type found in the tumour stroma. Human umbilical vein endothelial 
cells (HUVECs) are cells derived from the endothelium of veins from the 
umbilical cord and are commonly to be used for physiological and 
pharmacological investigations, such as macromolecule transport, blood 
coagulation, angiogenesis, and fibrinolysis. Human Umbilical Vein Endothelial 
Cells (HUVEC) single donor from Promo Cell Company was used. The cell 
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morphology in 2D cell culture was consistent with a typical cobblestone 
appearance, as expected (Figure 3.3). 
 
 
Figure 3.3. Human umbilical vein endothelial cells (line HUVECs) and at day 3 imaged using 
normal microscopy in 10x magnification 
 
 
3.2.  Metabolic activity of colorectal cancer cells and breast 
cancer cells in 2D and 3D cell culture (A/E & A/C) 
 
3.2.1. Detection of cell growth of both cell lines using alamarBlue  
 
The effectiveness of the alamarBlue assay for measuring cell proliferation, and 
cell growth was monitored (HT29, MCF7) for extended time periods. The figure 
below (3.4) was showed initial cell density for both cell lines in 2D after 5 h 
incubation with alamarBlue. The linear relationship demonstrated here gives 
confidence in the use of this assay, at the set parameters of dye concentration 




Figure 3.4: HT29 & MCF7 standard curve graph, shows initial cell density for both cell lines in 
2D after 5 h incubation with alamarBlue. Absorbance intensity was measured as a measure of 
growth (Excitation 530, Emission 620). There was a statistically significant difference between 
groups as determined by one-way ANOVA ***P<0.05. 
 
 
3.2.2. Optimum cell density for HT29 cancer cells in 3D cell culture 
using alamarBlue 
 
To map the viability of HT29 cells, alamarBlue was used to quantify metabolic 
activity of HT29 cells in 3D. Cells seeded at different concentrations 25x103, 
50x103, 75 x103, 100x103 and metabolic activity was checked at each cell 
density. From day 1 up to day 10 cells gradually started to grow for all different 
concentrations. The lowest level 25x103 cells/ml, showed little metabolic activity 
up to day 7 followed by a small drop to 30% at day 10. For 50x103 cells/ml, cell 
viability slowly was increased from 10% to 50% at day10. For both 75x103 

































The graph below (Figure 3.5) was showed results for HT29 cell line in 3D cell 
culture at different time points. 
 
 
Figure 3.5: The metabolic activity of HT29 cells at 4 different time points, confirms 100x103 is 
optimum cell density for 3D studies. Absorbance generated from the alamarBlue assay was used 
as a measure of growth. It increase significant over time compared to day1 for all time points 
(4,7,10). For each time point (mean  SD obtained from triplicates) there is significant in growth 
with increasing seeding concentration from 25K. There was a statistically significant difference 
between groups as determined by one-way ANOVA ***P<0.05.  
 
 
3.2.3. Optimum cell density for MCF7 cancer cells in 3D using 
alamarBlue 
 
The metabolic activity of MCF7 cell in 3D was measured as follows: cells were 
seeded in different concentrations 25x103, 50x103, 75 x103, 100x103 and 
metabolic activity was checked using alamarBlue assay at each cell density. 
From day 1 up to day 10 cells gradually started to grow for all different 
concentrations. At 25x103 cells/ml, cell viability increased only to 40% by day 
10. At 50x103 cells/ml, from day1 up to day10 viability rose from about 15% to 
approximately 50%. At 75x103 cells/ml, from day1 viability was increased from 
15% at day1 to almost 70% at the final day. And eventually, the highest 
concentration 100x103 cells/ml was showed dramatic increases in viability from 
15% to more 80% at day10.  
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Below graph (Figure 3.6) was showed results for MCF7 cell line in 3D at 
different time points.  
 
 
Figure 3.6: The metabolic activity of MCF7 cells at 4 different time points, confirms 100x103 is 
optimum cell density for 3D studies. Absorbance generated from the alamarBlue assay was used 
as a measure of growth. It increase significant over time compared to day1 for all time points 
(4,7,10). For each time point (mean  SD obtained from triplicates) there is significant in growth 
with increasing seeding concentration from 25K. There was a statistically significant difference 
between groups as determined by one-way ANOVA ***P<0.05. 
 
 
These results suggest that growth of both cell lines (HT29 and MCF7) are linear 
and demonstrable over the timeline of the experiments up to day 10, at seeding 
concentrations of 75x103 cells/ml and 100x103 cells/ml. 100x103 cells/ml was 
the level chosen for further experiments. 
 
 




3.3.1. Growth of colorectal cancer cells in the agar/collagen (A/C) matrix. 
 
Colorectal cancer cells (HT29) were seeded at 100x103 cells/ml concentration 
in A/C matrices in 24 well plates, as described in the methodology chapter. 
Miniwells were created by the addition of glass beads in A/C, and this followed 
by filling in the wells formed by the beads with HT29 cells. The final construct 
termed a tumouroid. These were left to grow over time and observed at specific 
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time points. At day 1, HT29 cells appeared to reside within the wells formed by 
the glass beads, with no sign of cell clumping and attachment. At Day 4, cells 
started clumping together. At day 7 cells continued to clump or aggregate and 
hence began to grow into spheroids. Finally, at day 10, small numbers of 
spheroids were fully formed (Figure 3.7). 
 
 
Figure 3.7: Cancer cells (HT29) growing in an agar/ collagen 3D matrix. Day1: Some cancer cells 
start clumping together, Day4: Some signs of small cell clumps, Day7: Clumps of cells slowly start 
to form spheroids. Day10: Small number of spheroids are completely formed. (Images taken using 












At day 10 spheroids were harvested for further experimentation. The figure 
below (3.8) shows the cancer spheroids growth rate in A/C from day 1 up to 
day 10. At day 1 and day 4 there was not much difference between spheroids 
sizes, with sizes less than 50 µm, however at day 7 spheroids roughly were 
about 50 µm and at day 10 they were about 80 µm in size.  
 
 
Figure 3.8: Cancer spheroids growth rate slightly increased from day 1 up to day 7. From day 7 
diameter size dramatically increased. (numbers shown as averages of 100 spheroids over 3 
independent experiments, measured by ImageJ). It increase significant over time compared to 
day1 for all time points (4,7,10) (mean  SD obtained from triplicates). There was a statistically 
significant difference between groups as determined by one-way ANOVA ***P<0.05. 
 
 
3.3.2. Growth of colorectal cancer cells in the A/E matrix. 
 
Colorectal cancer HT29 cells also were seeded in the A/E matrix. Initial seeding 
concentrations and methods used were similar as those described above 
(1.3.1) and in methodology chapter. At day 1, HT29 cells were showed to reside 
within the wells formed by the glass beads. However, unlike in the A/C matrix, 
there were some signs of cell clumping and attachment. Also, there were some 
small spheroids already formed. At Day 4, more spheroids appeared in different 
sizes. At day 7 bigger spheroids formed and migrated outside the wells 
originally made by the addition of glass beads. 10 days after creating the 3D 


























At day 10 only a few single cells appeared in A/E matrix compare to the A/C 
matrix. Therefore, the growth rate was better, and spheroids formed well; this 




Figure 3.9: Cancer cells (HT29) growing in an agar/ egg white 3D matrix Day1: Some cancer cells 
start clumping together, Day4: Some sign of cell clumps, and spheroids formation. Day7: spheroid 
structure formed. Day10: Large structures of spheroids are completely formed. (Images taken 














The below (Figure 3.10) showed cancer spheroids growth rate in A/E from day 
1 up to day 10, at which point spheroids were harvested. Hence, at day 1 
spheroids sizes were about 20 µm (average of 100 spheroids), at day 4 there 
was some increase (50 µm), however at day 7 spheroids sizes were grown to 
about 80 µm and finally at day 10 there were highly dense of spheroids roughly 
about 140 µm. 
 
 
Figure 3.10: Cancer spheroids growth rate slightly increased from day 1 up to day 7. From day 7 
dramatically increased up to day 10. (numbers shown as averages of 100 spheroids over 3 
independent experiments, measured by ImageJ). It increase significant over time compared to 
day1 for all time points (4,7,10) (mean  SD obtained from triplicates). There was a statistically 
significant difference between groups as determined by one-way ANOVA ***P<0.05. 
 
 
3.3.3. Growth of breast cancer cells in the A/C matrix 
 
MCF7 breast cancer tumouroids were created in the A/C matrix, by the exact 
method described above. The creation of wells in the A/C matrix by the addition 
of glass beads and afterward filling in the wells created by the beads with MCF7 
100x103 cells/ml. At day 1, MCF7 cells appeared to reside within the wells 
formed by the glass beads, with no sign of cell clumping and attachment. At 
Day 4, some cells started aggregating together. At day 7 all cells gradually 
began to clump and hence began to grow into spheroids. At day 10 there were 
some of the spheroids fully formed, and some cells appeared as single or in 

























Figure 3.11: Cancer cells (MCF7) growing in an agar/ collagen 3D matrix Day1: Some cancer cells 
start clumping together, Day4: Some sign of cell clumps, Day7: Clumps of cells slowly start to form 
spheroids. Day10: Small number of spheroids is completely formed. (Images taken using light 































The below (Figure 3.12) shows cancer spheroids growth rate A/C from day 1 
up to day 10, before harvesting spheroids. At day 1 the average sizes of 
clumping cells/spheroids were about 20 µm. At day 4 sizes slightly increased 
to about 30 µm, however at day 7 spheroids sizes sufficiently structured at 
about 50 µm, and finally, at day 10 spheroids sizes were roughly about 60 µm 
(average of 100 spheroids). 
 
 
Figure 3.12: Cancer spheroids growth rate increased frequently from Day 1 up to Day 10. 
(numbers shown as averages of 100 spheroids over 3 independent experiments, measured by 
ImageJ). It increase significant over time compared to day1 for all time points (4,7,10) (mean  SD 
obtained from triplicates). There was a statistically significant difference between groups as 
determined by one-way ANOVA ***P<0.05. 
 
 
3.3.4 Growth of breast cancer cells in the A/E matrix 
 
MCF7 breast cancer tumouroids were created in the A/E matrix, by the exact 
method described above, the creation of wells in the A/E matrix by the addition 
of glass beads and filling in the wells created by the beads with 100x103 cells/ml 
MCF7 cells. At day 1, MCF7 cells appeared to reside within the wells formed 
by the glass beads, with some sign of cell clumping and attachment. At Day 4, 
there were some signs of clumping cells. At day 7 clumping cells started to grow 
into spheroids. 10 days after creating the 3D tumouroids, small numbers of 
structures of spheroids were fully formed (Figure 3.13). At day 10 a few single 





























Figure 3.13: Cancer cells (MCF7) growing in an agar/ egg 3D matrix Day1: Some cancer cells start 
clumping together, Day4: Some sign of cell clumps, Day7: Clumps of cells slowly start to form 
spheroids. Day10: Small number of spheroids is completely formed. (Images taken using light 
















The below (Figure 3.14) shows cancer spheroids growth rate in A/E from day 1 
up to day 10, before harvesting spheroids. At day 1 the average sizes of 
clumping cells were about 20 µm, at day 4 small spheroids formed with an 
average size about 40 µm, however, at day 7 spheroids sizes increased to 
about 60 µm. Finally, at day 10 spheroids sizes dramatically increased to 
roughly about 120 µm (average of 100 spheroids). 
 
 
Figure 3.14: Cancer spheroids growth rate increases from Day 1 up to Day 7, and from Day 7 
dramatically increases up to day 10. (numbers shown as averages of 100 spheroids over 3 
independent experiments, measured by ImageJ). It increase significant over time compared to 
day1 for all time points (4,7,10) (mean  SD obtained from triplicates). There was a statistically 
significant difference between groups as determined by one-way ANOVA ***P<0.05. 
 
 
3.4. Propagation of cancer cells as spheroids, in 3D A/E matrix 
 
 
Spheroids were harvested from the tumouroid constructs by centrifugation and 
reseeded into the 3D new matrix to demonstrate whether cells could passage 
in 3D or not. Harvesting was only attempted for the A/E model. At day 10 after 
manufacture of 3D tumouroids, when finally, HT29 & MCF7 spheroids were fully 
formed the whole soft tumouroid underwent 5 min gentle spinning using 
centrifuge at 80 g, and resultant spheroids were transferred back into the new 
A/E condition. The spheroids appeared to have kept their morphology, although 






















The below images (Figure 3.15) shows HT29 spheroids and (Figure 3.16) 
shows MCF7 spheroids just one hour after the transferring process into the 
fresh A/E matrix. 
 
   
Figure 3.15: HT29 spheroids harvested and transferred back into fresh A/E matrix. (Images taken 





Figure 3.16: MCF7 spheroids harvested and transferred back into fresh A/E matrix. (Images taken 






3.5. The physical properties of the new 3D matrix 
 
 
3.5.1. Sodium Carboxymethylcellulose + Bovine Gelatine 
 
As described in the methodology chapter CMC was dissolved in water and 
brought to the boil. After cooling and standing in the fridge overnight to complete 
dissolution, gelatine was added to the CMC solution and mixed thoroughly. The 
compound was autoclaved at 121oC for 25 mins to be sterilized and cooled. 
The mixture was now x2 concentrated, so to use it was diluted 1:2 with growth 
medium and mixed gently, diluted further if too viscous.  
As it has mentioned in the method section physical property is essential to 
record, therefore viscosity level and water swelling capability of the solution was 
analysed. 
3.5.2. Viscosity properties of Carboxymethycellulose (CMC)+gelatine & 
Carboxymethycellulose (CMC) 
 
A viscometer was used as an instrument to measure the viscosity of fluid. 1 ml 
of CMC+gelatine solution was added to rheometer (the lower measuring 
system), and viscosity level checked using viscometer and compared with the 
viscosity of CMC solution (No gelatine) at room temperature. The figure 3.17 
below shows the rheometer (Cone/plate system).  
 
Figure 3.17: Rheometer (Cone/plate) measuring system contains of a rotating upper Cone and a 
fixed lower plate with CMC mixture contained between them. Since the shear stress is constant 
(within 0.3%) with radial position for Cones with a small Cone angle, the viscosity of CMC mixture 
can be analysed directly from the experimental torque/speed relation. For Cone/plate measuring 
system, it is normally easier to slightly over fill and then trim off any excess sample after bringing 
the upper and lower measuring systems together. 
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The below figures show the viscosity level of CMC+gelatine and CMC solution 
(No gelatine). Therefore, the results showed CMC+gelatine viscosity was 
slightly higher than CMC solution (No gelatine). Although the viscosity level is 
significant, it is important that it does not interfere with 3D harvesting.   
 
Figure 3.18: The (blue line) indicates viscosity level of CMC+gelatine and (Red Line) represent 
shear stress, measured by Cone/plate measuring system.  
 
 
Figure 3.19: The (blue line) indicates viscosity level of CMC and (Red Line) is shear stress. 






3.5.3. 3D CMC water swelling capability 
 
Water swelling capability properties was checked using freeze-drying which is 
a dehydration process. The below (Figure 3.19) shows water swelling capability 
process, where freeze dried CMC mixtures was weighted, and compared with 
the actual weight of CMC mixture. The 24 ultra-low binding plate weighed 71.00 
gr (+/-). Then the 24 ultra-low binding plate containing 1 ml of solution weighed 
73.00 gr (+/-) and eventually after freeze-drying the 24 ultra-low binding plate 
containing dried CMC+gelatine solution weighed 69.00 gr (+/-).  
 
 
Figure 3.20: Three stages of water swelling capability process,1. The 24 Ultra Low Binding plate 
weighted. 2. The 24 Ultra Low Binding plate weighted after adding of 1 ml solution. 3. The 24 Ultra 




















3.6.  Metabolic activity of cancer cells in the novel 3D matrix 
 
As it has mentioned in the methodology section, different cell densities were 
seeded into CMC mixture (in 24 ultra-low binding plates) for both HT29 and 
MCF7 cancer cells. The below (Figures 3.20, 3.21) show results of growth, 
measured as metabolic activity (alamarBlue) over 3 independent experiments. 
 
3.6.1. Optimum cell density of colorectal cancer cells in CMC+gelatine 
 
The lowest seeding concentration of HT29 25x103 cells/ml showed an increase 
in metabolic activity/growth from day 1 up to day 7 however, at day10, this 
dropped to less than 60%. 50x103 cells/ml cell density showed a smooth 
increase from day 1 up to day 10. 100x103 cells/ml showed the highest 
continuous increase from day 1 up to day 10. And eventually the highest 
concentration 150x103 cells/ml showed a dramatic increase from day 1 up to 
day 7, and a dramatic drop for day 10 from over 90% to less than 70%.  
               
Figure 3.21: The metabolic activity of different HT29 seeding concentrations compared at four 
different time points. Metabolic activity was measured by alamarBlue and taken as an indication 
of growth. The results show 100K is the optimum cell density. It increase significant over time 
compared to day1 for all time points (4,7,10). For each time point (mean  SD obtained from 
triplicates) there is significant in growth with increasing seeding concentration from 25K. There 






3.6.2. Optimum cell density of breast cancer cells in CMC+gelatine 
 
The below (Figure 3.21) shows MCF7 growth slightly increased from day 1 up 
to day 7, however, there was a plateau between day 7 and day 10 at the lowest 
concentration 25x103 cells/ml. The 50x103 cells/ml cell density of MCF7 
showed the continuous increase from day 1 up to day 10. By increasing cell 
density of MCF7 to 100x103 cells/ml the measurements showed a constant 
increase from day 1 up to day 10 which was larger than that observed for 
50x103 cells/ml. Finally, MCF7 showed a dramatic increase from day 1 up to 
day 7, and dramatic drop at day 10 for the highest seeding concentration of 
150x103 cells/ml.  
 
Figure 3.22: The metabolic activity of different MCF7 seeding concentrations compared at four 
different time points. Metabolic activity was measured by alamarBlue and taken as an indication 
of growth. The results show 100K is the optimum cell density. It increase significant over time 
compared to day1 for all time points (4,7,10). For each time point (mean  SD obtained from 
triplicates) there is significant in growth with increasing seeding concentration from 25K. There 













3.7.  Growth of cancer cells in the novel 3D matrix (CMC+gelatine 
matrix) 
 
100x103 cells/ml were seeded into the 3D CMC+gelatine matrix and growth rate 
of spheroids tracked and compared over different time points. The below 
figures show results from 3 independent experiments. 
 
3.7.1 Growth of colorectal cancer cells in CMC+gelatine matrix. 
 
At day 1 HT29 small spheroids were already formed with sizes of about 80 m 
in average. At day 4 spheroid size considerably increased to about 175 m in 
average, at day7 spheroid size increased to more than 200 m and finally at 
day10 growth (as measured by diameter) started slowing down, with highly 
dense spheroids of about 220 m in average (Figures 3.22, 3.23). 
 
 
Figure 3.24: colorectal cancer cells growth in 3D CMC+gelatine. Day1: small spheroids formed. 
Day4: spheroids fully structured. Day:7 spheroid size increased. Day10: highly dense spheroids 




Figure 3.25: Growth rate of HT29 cancer cells in 3D CMC+gelatine matrix, Spheroid size increases 
between 1- 7 days’ post seeding, with sizes starting to reach a plateau by day 10. Day1: spheroid 
size about 75 mm. Day 4:  spheroids size about 170 mm. Day7: spheroids size increased to 200 mm. 
Day10: spheroids size about 210 mm. (numbers shown as averages of 100 spheroids over 3 
independent experiments, measured by ImageJ). It increase significant over time compared to 
day1 for all time points (4,7,10) (mean  SD obtained from triplicates). There was a statistically 
significant difference between groups as determined by one-way ANOVA ***P<0.05. 
 
 
3.7.2 Growth of breast cancer cells in CMC+gelatine matrix. 
 
At day1 post seeding, MCF7 cells appeared to start forming into small 
spheroids, which were about 75 m in average. At day 4 spheroid size 
dramatically increased to about 85 m. At day 7 spheroids size was increased 
to more than 135 m. And finally, at day 10 growth, as measured by diameter, 
started slowing: there were highly dense spheroids within the matrix with sizes 
which slightly increased to about 180 m (Figures 3.24, 3.25). Overall, the 

























Figure 3.26: breast cancer cells growth in 3D CMC+gelatine. Day1: small spheroids formed. Day4: 




Figure 3.27: Growth rate of MCF7 cancer cells in 3D CMC+gelatine matrix, Spheroid size 
increases between 1- 7 days’ post seeding, with sizes starting to reach a plateau by day 10. Day1: 
spheroid size about 55 mm. Day 4:  spheroids size about 85 mm. Day7: spheroids size increased to 
135 mm. Day10: spheroids size about 180 mm. (numbers shown as averages of 100 spheroids over 
3 independent experiments, measured by ImageJ). It increase significant over time compared to 
day1 for all time points (4,7,10) (mean  SD obtained from triplicates). There was a statistically 





















3.8. Growth of human umbilical vein endothelial cells in 
CMC+gelatine matrix. 
 
100x103 cells/ml HUVECs seeded into the 3D matrix and growth rate tracked 
and compared over different time points, Days 1, Day 5 and Day 10. The 
(Figure 3.26) below shows representative results, of HUVECs morphology in 
3D; this was changed compared to 2D (Figure 3.3), with cells in 3D appearing 
rounded. The number of HUVECs seemed to have slightly increased from day 
1 up to day 10. Finally, at day10 HUVECs were transferred back into the 2D 
condition to check whether they are live or dead. Crucially, HUVECs did not 
grow as spheroids or aggregates, which was the behaviour observed with 
cancer cell lines. 
Figure 3.28: HUVECs compared over 3 different time points from day1 up to day10. (Images taken 
using light microscopy.) 
 
Figure 3.29: At day10 HUVECs were transferred back into the 2D condition to check whether they 
alive or not. Image taken using fluorescence microscopy.  
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3.9. Live/Dead Evaluation (Propidium Iodide and FDA) 
 
It is crucial to determine and confirm the viability of spheroids either while 
growing within the 3D matrices or harvested after centrifugation of the 3D 
tumouroids, which was determined by the live/dead assay, using Propidium 
Iodide and FDA, which are detectable by fluorescent microscopy. Results for 
both colorectal cancer cells and breast cancer cells are shown below, at 
different time points after tumouroid manufacture, days 1, 5 and 10. 
 
3.9.1 Viability of colorectal cancer cells in CMC and gelatine matrix 
(Live/Dead Assay) 
 
At day1 staining of HT29 spheroids showed a weak signal of composite of FDA 
and PI signal due to small spheroids (Figure 3.26). At day 5 HT29 spheroids 
showed better signal and high cell viability. Eventually at day10 spheroids 
showed slightly weaker signal, mostly the internal structure of the spheroids 
surrounded by a layer of viable cells. 
 
Figure 3.30: Live/Dead Assay in HT29 3D spheroids CMC+gelatine, Day1 clumping cells and small 
spheroids show weak signal. Fluorescein diacetate (FDA) and propidium iodide (PI), which stain 
viable cells (Green) and dead cells (Red), respectively. 
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3.9.2 Viability of breast cancer cells in CMC and gelatine matrix 
(Live/Dead Assay) 
  
At day1 staining of MCF7 small spheroids showed a weak signal of composite 
of FDA and PI signal (Figure 3.27). At day 5 MCF7 spheroids showed the 
stronger signal of composite of FDA and PI. At day10 most MCF7 spheroids 
revealed high cell viability, mostly the internal structure of the spheroids 
surrounded by a layer of viable cells. 
 
 
Figure 3.31: Live/Dead Assay in MCF7 3D spheroids CMC+gelatine, Day1 clumping cells and 
small spheroids show weak signal. Fluorescein diacetate (FDA) and propidium iodide (PI), which 























3.10. Levels of oxygen/ Hypoxia of 3D cultured cancer cells.  
 
Hypoxia levels of HT29 and MCF7 spheroids were checked through specific 
time points. Both cell lines were seeded into the CMC+gelatine 3D matrices 
and hypoxia level was checked using Image-iT Hypoxia reagent. It is non-
fluorescent when live cells are in the 3D model with normal oxygen 
concentrations and becomes fluorescent when oxygen levels decrease. 
Spheroids oxygen level with less than 5% indicates higher red fluorescence, 
therefore, there were more hypoxic than live cells in 3D model with no 
fluorescent.   
Image-iT Hypoxia reagent was added to HT29 spheroids within CMC+gelatine 
3D matrix. HT29 spheroids (Figure 3.28) tracked and imaged using confocal 
imaging microscopy over different time points, at day1 there is no sign of any 
fluorescence when live cells were within CMC 3D matrix. At day 4 while 
spheroids were well-formed, oxygen level started to drop to less than 5%. At 
day 7 larger size of spheroids were formed with higher fluorescence intensity 
according to the fluorescence scale bar. Eventually at day 10 whole 3D matrix 
and large spheroids showed the highest level of intensity, before the harvesting 
step. For the control group, HT29 spheroids within CMC+gelatine 3D model 
was tracked and imaged over different time points, using confocal imaging 
microscopy without any reagent added to the matrix. 
Image-iT Hypoxia reagent was added to MCF7 spheroids within CMC+gelatine 
3D model. MCF7 spheroids (Figure 3.28) were tracked and imaged using new 
instructed confocal imaging microscopy over the particular time frame, at day 1 
there is no sign of any fluorescence when live cells were within CMC 3D matrix. 
At day 4 while spheroids were well-formed, oxygen level started to drop to less 
than 5%. At day 7 larger size of spheroids was formed shown stronger 
fluorescence intensity. At final time point, whole 3D matrix and large spheroids 
were showed the highest level of intensity, before the harvesting step. To check 
the effects of reagent MCF7 spheroids within CMC+gelatine 3D model was 
tracked and imaged over different time points, using new instructed confocal 
imaging microscopy without any reagent added to the matrix. 
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      Figure 3.32: shows oxygen gradient (fluorescence) of grown spheroids on both cell lines within 
3D matrix at different time points based on fluorescence intensity. 
 
 
3.11. Propagation of cancer cells as spheroids, in 3D 
CMC+gelatine matrix 
 
Once live/dead assay and oxygen level of spheroids were checked, at day 10 
when grown spheroids were ready to be harvested for further studies. Grown 
spheroids were transferred into the new 3D matrix, where spheroids could be 









The (Figure 3.29) below shows the harvested grown HT29 spheroids at day 10 
after being transferred into the new CMC+gelatine matrix. 
 
Figure 3.33: shows harvested HT29 grown spheroids at day 10 (20x). 
 
 
The (Figure 3.29) below shows the harvested grown MCF7 spheroids at day 10 
after being transferred into the fresh new CMC+gelatine matrix.  
 














3.12.1. Synthesis of AuNCs 
 
AuNCs manufacture is not presented in detail in this report, as their synthesis 
was part of another study (kindly provided by Dr. B Ramesh, UCL Division of 
Surgery and Interventional Science). The figure below shows the AuNCs final 
chemical structure (Figure 3.31). 
 
 




3.12.2. Measuring AuNCs size  
 
 
The AuNCs sizes were measured using TEM imaging, (Figure 3.32) which 
indicated an average core diameter size of AuNCs 2 nm (standard division 0.67 
+/-). According to dynamic light scattering analysing, the hydrodynamic 
diameter size was 3.5 nm. The AuNCs are considered as appropriate 




Figure 3.36: TEM image of dispersed AuNCs show the average diameter of (2nm) (standard 
division 0.67 +/-). 
 
 
3.13. Toxicity of AuNCs in 2D cultures of all cell lines. 
 
The (Figure 3.36) below shows cells exposed to equivalent concentrations of 
AuNCs and the primary chemical salts used for AuNCs manufacture HAuCL4 
(Mercaptosuccinic acid, Gold (III) chloride trihydrate, and Dimethylformamide). 
The results for HT29 colorectal cancer cells indicated that gold salts (HAuCL4) 
conferred a higher level of toxicity compared to AuNCs, over all concentrations. 
From the lowest concentration 50 µg/ml to the largest concentration of HAuCL4 
the number of viable cells dramatically dropped to less the 50%. The AuNCs 
conferred less toxicity than HAuCL4 compared to each salt concentration. 
However, exposure to AuNCs resulted in a drop-in viability to approximately 
70%.  
 
The results for MCF7 breast cancer cells indicated a decreased viability with 
exposure to increasing (HAuCL4) gold salt concentrations ranging from 
relatively small decreases to 75% for 50, 100 and 150 µg/ml to a dramatic drop 
to less than 50% for 200 µg/ml. Contrary to this exposure to AUNCs resulted in 
significantly smaller reductions in viability, with a maximum of 20% drop (80% 
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viability) or the highest concentrations of the AUNCs. The decrease in viability 
caused by the gold salts was significant compared to control untreated cells, 
while the reduction in viability caused by AuNCs was only significant versus 
control for the high concentration of 200 µg/ml.  
Finally, the results for HUVECs indicated that gold salts (HAuCL4) decreased 
viability (increased toxicity) with exposure to increasing (HAuCL4) gold salt 
concentrations. The results show a dramatic drop to less than 20% for all 50, 
100, 150 and 200 µg/ml. The AuNCs conferred less toxicity than HAuCL4 
compared to each salt concentration. However, exposure to AuNCs resulted in 
a dramatic drop in viability at higher concentrations to approximately 60% 
(Figure 3.37). 
 
A                                                                                                                         B 
 
                                            C 
 
Figure 3.37: (A) alamarBlue assay measurements showing HT29 colorectal cancer cell viability. 
AuNCs confer a level of toxicity, which remains constant at different concentrations.  With 
HAuCL4 cell viability dramatically dropped to less than 50% over all concentrations, P < 0.0001. 
Results are shown as % of untreated controls. (B) alamarBlue assay measurements showing MCF7 
cell viability. AuNCs confer a level of toxicity, which remains constant at different concentrations.  
With HAuCL4 cell viability resulted in small decreases to 75% lower concentrations to a dramatic 
drop to less than 50% for 200 µg/ml, P < 0.0001. Results are shown as % of untreated controls. (C) 
alamarBlue assay shows HUVECs cell viability. AuNCs frequent toxicity level at different 
concentrations. HAuCL4 cell viability dramatically dropping to very least amount at different 
concentrations, ***P<0.05. for each condition (mean  SD obtained from triplicates). Significantly 
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3.14. Targeting cells in 2D (fixed), using AuNCs-Anti-EGFR  
 
Fluorescent AuNCs were conjugated to commercial EGFR antibody. HT29 and 
MCF7 cancer cells (2D) were fixed and then targeted using AuNCs-Anti-CRT 
and AuNCs.  
 
3.14.1. Binding of AuNCs to fixed HT29 cells in 2D. 
 
Both AuNCs-Anti-EGFR and AuNCs were applied to fixed HT29 colorectal 
cancer cells, which had been grown in 2D culture. Incubation lasted for one 
hour, cells were then washed and imaged using confocal imaging microscopy. 
Binding on HT29 cells was demonstrated only for targeted AuNCs-Anti-EGFR, 
but not for non-targeted AuNCs. A degree of binding, as shown by the NIR 
fluorescent (Pseudo colour) apparent mostly on the cell surface, was evident in 
most HT29 cells. The results (Figure 3.38) are shown as light transmission, 
fluorescence and merged images (respectively, A, B, C).  
       A) Light transmission                 B) Fluorescence                         C) Merged 
 
 
Figure 3.38: The top panel shows light transmission, fluorescence and merged images of fixed 
EGFR-expressing HT29 colorectal cancer cells grown in 2D, after incubation with targeted 
AuNCs-Anti-EGFR. For the control the bottom panel shows light transmission, fluorescence and 
merged of fixed EGFR expressing HT29 cells grown in 2D, after exposure to untargeted AuNCs.  
Both AuNCs molecules emit in the near infrared (700 nm) and therefore can be imaged at red 
colour by confocal microscopy.  
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3.14.2. Binding of AuNCs to fixed MCF7 cells in 2D. 
 
Both AuNCs-Anti-EGFR and AuNCs were applied to fixed MCF7 breast cancer 
cells, which had been grown in 2D culture. Incubation lasted for one hour, cells 
were then washed and imaged using confocal imaging microscopy. Binding on 
MCF7 cells was demonstrated only for targeted AuNCs-Anti-EGFR, not for non-
targeted AuNCs. A degree of binding, as shown by the NIR fluorescent (Pseudo 
colour) apparent mostly on the cell surface, was evident in most MCF7 cells. 
The results (Figure 3.39) are shown as light transmission, fluorescence and 
merged (respectively, A, B, C). 
 
       A) Light transmission                 B) Fluorescence                         C) Merged 
 
 
Figure 3.39: The top panel shows light transmission, fluorescence and merged images of fixed 
EGFR-expressing MCF7 breast cancer cells grown in 2D, after incubation with targeted AuNCs-
Anti-EGFR. For the control the bottom panel shows light transmission, fluorescence and merged 
of fixed EGFR expressing MCF7 cells grown in 2D, after exposure to untargeted AuNCs.  Both 












3.15. Immuno-chemiluminescence detection of bio conjugated 
AuNCs 
 
AuNCs were conjugated to Anti-Calreticulin and kindly provided by Dr. B 
Ramesh, UCL Division of Surgery and Interventional Science). Immuno-
chemiluminescence detection was carried to further validate conjugation of the 
AuNCs-Anti-CRT via dot blot. There were no changes in fluorescence intensity 
or shift in spectra position despite modification. CRT peptides spotted onto 
PVDF membrane, were targeted using AuNCs-Anti-CRT. The following spots, 
A, B, C confirmed the conjugation of AuNCs-Anti-CRT via dot blot, although as 
different amounts of AuNCs-Anti-CRT were applied, hence, amounts of 
targeted CRT peptide changed.  The (Figure 3.40) below showed decreasing 
amounts of targeted CRT peptide from A, B, C respectively. For the control, D 
showed glutathione peptide.  
 
 
Figure 3.40: Dot blots of AuNCs-Anti-CRT (titre 1:1000) binding to CRT peptides spotted on 
PVDF membranes. Decreasing amounts of CRT (A-C) and control dot (D, glutathione peptide). 
(triplicate blots)  
 
 
3.16. Targeting cells in 2D (fixed cells), using AuNCs-Anti-CRT 
 
For primary targeting studies, 2D culture systems are optimal, as the flat 
morphology allows for clarity of imaging. The cancer cells HT29, MCF7 and 
endothelial cells HUVECs were fixed and then targeted using AuNCs-Anti-CRT 










3.16.1. Colorectal cancer cells targeted using AuNCs-Anti-CRT (2D fixed 
cells) 
 
The (Figure 3.37) below showed the application of AuNCs-Anti-CRT and 
AuNCs on fixed (2D) HT29 cancer cells. 100 μl of AuNCs-Anti-CRT and AuNCs 
applied to HT29 cells in 2D format. 1-hour after applying, HT29 cells were 
washed x3 with PBS and imaged using confocal imaging microscopy.  
 
Both AuNCs-Anti-CRT and AuNCs were applied to fixed HT29 colorectal 
cancer cells, which had been grown in 2D culture. Incubation lasted for one 
hour, HT29 cells were then washed and imaged using confocal imaging 
microscopy. Binding on HT29 cells was demonstrated only for targeted AuNCs-
Anti-CRT, not for non-targeted AuNCs. A degree of binding, as shown by the 
NIR fluorescent (Pseudo colour) apparent mostly on the cell surface, was 
evident in most HT29 cells. The results (Figure 3.41) are shown as light 
transmission, fluorescence and merged (respectively, A, B, C). 
       A) Light transmission                 B) Fluorescence                         C) Merged 
  
  
Figure 3.41: The top panel shows light transmission, fluorescence and merged images of fixed 
CRT-expressing HT29 colorectal cancer cells grown in 2D, after incubation with targeted AuNCs-
Anti-CRT. For the control the bottom panel shows light transmission, fluorescence and merged of 
fixed CRT expressing HT29 cells grown in 2D, after exposure to untargeted AuNCs.  Both AuNCs 
molecules emit in the near infrared (700 nm) and therefore can be imaged at red colour by confocal 
microscopy. 
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Both AuNCs-Anti-CRT and AuNCs were applied to fixed MCF7 breast cancer 
cells, which had been grown in 2D culture. Incubation lasted for one hour, cells 
were then washed and imaged using confocal imaging microscopy. Binding on 
MCF7 cells was demonstrated only for targeted AuNCs-Anti-CRT, not for non-
targeted AuNCs. A degree of binding, as shown by the NIR fluorescent (Pseudo 
colour) apparent mostly on the cell surface, was evident in most MCF7 cells. 
The results (Figure 3.42) are shown as light transmission, fluorescence and 
merged (respectively, A, B, C). 
 
       A) Light transmission                 B) Fluorescence                         C) Merged 
  
 
Figure 3.42: The top panel shows light transmission, fluorescence and merged images of fixed 
CRT-expressing MCF7 breast cancer cells grown in 2D, after incubation with targeted AuNCs-
Anti-CRT. For the control the bottom panel shows light transmission, fluorescence and merged of 
fixed CRT expressing MCF7 cells grown in 2D, after exposure to untargeted AuNCs.  Both AuNCs 















3.16.3 HUVECs targeted using AuNCs-Anti-CRT (2D fixed cells) 
 
 
Both AuNCs-Anti-CRT and AuNCs were applied to fixed HUVECs endothelial 
cells, which had been grown in 2D culture. Incubation lasted for one hour; 
endothelial cells were then washed and imaged using confocal imaging 
microscopy. Binding on endothelial cells was not revealed for either of targeted 
AuNCs-Anti-CRT and non-targeted AuNCs. The results (Figure 3.43) are 
shown as light transmission, fluorescence and merged (respectively, A, B, C). 
 
       A) Light transmission                 B) Fluorescence                         C) Merged 
 
 
Figure 3.43: The top panel shows light transmission, fluorescence and merged images of fixed 
CRT-expressing HUVECs endothelial cells grown in 2D, after incubation with targeted AuNCs-
Anti-CRT. For the control the bottom panel shows light transmission, fluorescence and merged of 
fixed CRT expressing HUVECs cells grown in 2D, after exposure to untargeted AuNCs.  Both 




























3.17.1 Colorectal cancer cells targeted using AuNCs-Anti-CRT and 
AuNCs (2D live) 
 
Both AuNCs-Anti-CRT and AuNCs were applied to live HT29 colorectal cancer 
cells, which had been grown in 2D culture. Incubation lasted for one hour; cells 
were then washed and imaged using fluorescence imaging microscopy. 
Binding on HT29 cells was determined only for targeted AuNCs-Anti-CRT, not 
for non-targeted AuNCs. A degree of binding, as shown by the NIR fluorescent 
(Pseudo colour) apparent mostly on the cell surface, was evident in most HT29 
cells. The results (Figure 3.44) are shown as light transmission, fluorescence 
and merged (respectively, A, B, C). 
 
       A) Light transmission                 B) Fluorescence                         C) Merged 
 
 
Figure 3.44: The top panel shows light transmission, fluorescence and merged images of live HT29 
cells grown in 2D, after incubation with targeted AuNCs-Anti-CRT. For the control the bottom 
panel shows light transmission, fluorescence and merged of live HT29 cells grown in 2D, after 




3.17.2 Breast cancer cells targeted using AuNCs-Anti-CRT and AuNCs 
(2D live) 
 
Both AuNCs-Anti-CRT and AuNCs were applied to live MCF7 breast cancer 
cells, which had been grown in 2D culture. Incubation lasted for one hour; cells 
were then washed and imaged using fluorescence imaging microscopy. 
Binding on MCF7 cells was demonstrated only for targeted AuNCs-Anti-CRT, 
not for non-targeted AuNCs. A degree of binding, as shown by the NIR 
fluorescent (Pseudo colour) apparent mostly on the cell surface, was evident in 
most MCF7 cells. The results (Figure 3.45) are shown as light transmission, 
fluorescence and merged (respectively, A, B, C). 
 
       A) Light transmission                 B) Fluorescence                         C) Merged 
 
 
Figure 3.45: The top panel shows light transmission, fluorescence and merged images of live MCF7 
cells grown in 2D, after incubation with targeted AuNCs-Anti-CRT. For the control the bottom 
panel shows light transmission, fluorescence and merged of live MCF7 cells grown in 2D, after 
exposure to untargeted AuNCs, (Images taken using fluorescence microscopy.) 
 
 
3.18. Targeting 3D fixed spheroids using AuNCs-Anti-CRT and 
AuNCs  
 
The spheroids harvested by centrifugation, after 10 days’ growth in 
CMC+gelatine 3D matrix was fixed and incubated with AuNCs, either 
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conjugated AuNCs-Anti-CRT or untargeted AuNCs, for control studies. After 
incubation, spheroids were gently centrifuged rinsed to remove excess and 
imaged using fluorescence microscopy. 
 
3.18.1. Colorectal cancer cells targeted using AuNCs-Anti-CRT (3D fixed) 
 
Fixed HT29 spheroids which were incubated with AuNCs-Anti-CRT showed 
uptake of the targeted AuNCs-Anti-CRT, as demonstrated by the red 
fluorescent images (Figure 3.46). Uptake appears more intense on the 
periphery/outer boundary of the spheroids. Counterstaining using DAPI (which 
binds to the A-T rich regions in the DNA and emits blue fluorescence) enabled 
the identification of cell nuclei and showed that spheroids are well populated, 
with probably more cells towards the periphery of the spheroid, and fewer cells 
at the core of the spheroid. (Figure 3.46) demonstrates targeting, showed by 
red fluorescence.  
 
 




Figure 3.46 A) shows staining HT29 spheroids with DAPI that releases blue fluorescence by bind 
to the A-T rich regions in DNA. B) shows targeted HT29 spheroids using conjugated AuNCs-Anti-
CRT. C) shows merged images of A and B. 
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3.18.2. Colorectal cancer cells targeted using AuNCs (3D fixed) 
 
For the control, fixed HT29 spheroids which were incubated with AuNCs 
showed uptake of the targeted AuNCs, as demonstrated by the red fluorescent 
images (Figure 3.47). Uptake appears in lower levels of fluorescence compared 
to spheroids in section (1.14.1) on the periphery/outer boundary of the 
spheroids. Counterstaining using DAPI (which binds to the A-T rich regions in 
the DNA and emits blue fluorescence) enabled the identification of cell nuclei 
and showed that spheroids are well populated, with probably more cells 
towards the periphery of the spheroid, and less cells at the core of the spheroid. 
(Figure 3.47) demonstrates targeting, demonstrated by red fluorescence.  
 
    




Figure 3.47: A) shows staining HT29 spheroids with DAPI that releases blue fluorescence by bind 
to the A-T rich regions in DNA. B) shows targeted HT29 spheroids using conjugated AuNCs. C) 









3.18.3. Breast cancer cells targeted using AuNCs-Anti-CRT (3D fixed) 
 
Fixed MCF7 spheroids which were incubated with AuNCs-Anti-CRT showed 
uptake of the targeted AuNCs-Anti-CRT, as demonstrated by the red 
fluorescent images (Figure 3.48). Uptake appears more intense on the 
periphery/outer boundary of the spheroids. Counterstaining using DAPI (which 
binds to the A-T rich regions in the DNA and emits blue fluorescence) enabled 
the identification of cell nuclei and showed that spheroids are well populated, 
with probably more cells towards the periphery of the spheroid, and fewer cells 
at the core of the spheroid. (Figure 3.48) demonstrates targeting, showed by 
red fluorescence.  
 
    




Figure 3.48: A) shows staining MCF7 spheroids with DAPI that releases blue fluorescence by bind 
to the A-T rich regions in DNA. B) shows targeted MCF7 spheroids using conjugated AuNCs-Anti-









3.18.4. Breast cancer cells targeted using AuNCs (3D fixed) 
 
For the control, fixed MCF7 spheroids which were incubated with AuNCs 
showed uptake of the targeted AuNCs, as demonstrated by the red fluorescent 
images (Figure 3.49). Uptake appears in lower levels of fluorescence compared 
to spheroids in section (1.14.3) on the periphery/outer boundary of the 
spheroids. Counterstaining using DAPI (which binds to the A-T rich regions in 
the DNA and emits blue fluorescence) enabled the identification of cell nuclei 
and showed that spheroids are well populated, with probably more cells 
towards the periphery of the spheroid, and less cells at the core of the spheroid. 
(Figure 3.49) demonstrates targeting, demonstrated by red fluorescence.  
 
    




Figure 3.49: A) shows staining MCF7 spheroids with DAPI that releases blue fluorescence by bind 
to the A-T rich regions in DNA. B) shows targeted MCF7 spheroids using conjugated AuNCs. C) 






3.19. Targeting live cancer spheroids through an endothelial cell 
barrier in a complex tumouroid construct, using AUNCs-anti-
CRT 
 
Having shown appropriate targeting capabilities of the AUNCs-Anti-CRT 
molecules, using variously fixed and live cell cultures, the purpose of this 
section was to investigate whether targeted AuNCs would differentiate their 
targets (CRT-expressing cancer cells) within a more complex 3D construct, 
which incorporates an endothelial barrier.  
 
To achieve this, HUVECs were seeded on a filter insert for 48 h. Now spheroids 
grown for 10 days were harvested and transferred into new CMC+gelatine 3D 
matrix at 6 well ultra-low binding plates, and the HUVEC-populated filters were 
placed on top. Shortly after this, conjugated AuNCs-Anti-CRT were applied 
onto the HUVEC-populated membrane and investigations of the fate of AuNCs 
took place 2 h later, using confocal microscopy. 
 
Control groups included constructs where “empty” (no HUVEC cells) filter 
inserts were placed on top of the 3D matrix containing grown spheroids. This 
helped to determine the barrier function of HUVECs. Further control groups 
consisted of constructs with HUVEC populated filters but no cancer spheroids 
in the CMC+gelatine 3D matrix. And a group where empty filter inserts were 
placed on top of CMC+gelatine 3D matrix with no spheroids. The procedure is 













Figure 3.50: The process of manufacturing complex 3D constructs, which contain both cancer 
spheroids in CMC+gelatine matrix and an endothelial cells barrier. A) shows the HUVECs seeded 
on filter insert, after 48 h, the grown spheroids harvested and transferred into new CMC+gelatine 
3D matrix and then conjugated AuNCs-Anti-CRT applied onto the HUVECs membrane. B) shows 
the empty filter insert placed on top of the grown spheroids harvested and then conjugated AuNCs-
Anti-CRT applied. C) HUVECs were seeded on filter insert, after 48 the filter inserts placed on 
top of the 3D model and then AuNCs-Anti-CRT applies onto empty CMC+gelatine 3D matrix. D) 
shows the empty filter insert placed on top of the 3D model and then AuNCs-Anti-CRT applied 






3.19.1. HUVECs growth on filter insert 
 
 
HUVECs were grown on filter inserts for 48 h to attempt to grow a layer of cells 
as confluent as possible. To demonstrate this, cells were stained with crystal 
violet and imaged by florescence microscopy. Figure 3.51 shows that cell nuclei 
took up crystal violet (green fluorescence).   
 
 
Figure 3.51: HUVECs were seeded on filter insert and 48 h later stained with crystal violet and 
imaged by fluorescence microscopy. The stain (green fluorescence) shows nuclear uptake.  
 
 
3.19.2. HT29 grown spheroids targeted using AuNCs-Anti-CRT 
 
 
The (Figure 3.52) below showed HT29 grown spheroids targeted using 100 µl 
of AuNCs-Anti-CRT by passing through HUVECs seeded on filter insert. The 
(Figure 3.52) also showed HT29 grown spheroids targeted using 100 µl of 
AuNCs-Anti-CRT by passing through empty filter insert. Both conditions were 
imaged using new imaging system 2 h after applying AuNCs-Anti-CRT and 
indicated HT29 grown spheroids targeted by passing through HUVECs seeded 






The (Figure 3.52) also showed specificity of targeting in grown spheroids by 
indicating low fluorescence intensity at these conditions. At this stage grown 
HT29 targeted spheroids harvested again for further studies.  
 
                   
Figure 3.52: H/C shows HT29 grown spheroids targeted using AuNCs-Anti-CRT by passing 
through HUVECs seeded on filter insert. NH/C shows HT29 grown spheroids targeted using 
AuNCs-Anti-CRT by passing through empty filter insert. H/NC shows a condition when HUVECs 
seeded on filter insert and placed on top of the 3D model and then AuNCs-Anti-CRT applies onto 
empty CMC+gelatine 3D matrix. NH/NC shows the empty filter insert placed on top of the 3D 
model and then AuNCs-Anti-CRT applies onto empty CMC+gelatine 3D matrix. These images 
taken use new optimised confocal microscopy.  
 
 
3.19.3. MCF7 grown spheroids targeted using AuNCs-Anti-CRT 
 
 
The (Figure 3.53) below showed MCF7 grown spheroids targeted using 100 µl 
of AuNCs-Anti-CRT by passing through HUVECs seeded filter insert. The 
(Figure 3.53) showed MCF7 grown spheroids targeted using 100 µl of AuNCs-
Anti-CRT by passing through empty filter insert. Both conditions imaged, 2 h 
after applying AuNCs-Anti-CRT using new imaging system and indicated MCF7 
grown spheroids targeted by passing through HUVECs seeded filter insert 
higher fluorescence intensity compared to the empty filter insert condition. 
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The (Figure 3.53) showed specificity of targeting in grown spheroids by 
indicating low fluorescence intensity at these conditions. At this stage grown 
MCF7 targeted spheroids harvested again for further studies.  
 
                   
Figure 3.53: H/C shows MCF7 grown spheroids targeted using AuNCs-Anti-CRT by passing 
through HUVECs seeded on filter insert. NH/C shows MCF7 grown spheroids targeted using 
AuNCs-Anti-CRT by passing through empty filter insert. H/NC shows a condition when HUVECs 
seeded on filter insert and placed on top of the 3D model and then AuNCs-Anti-CRT applies onto 
empty CMC+gelatine 3D matrix. NH/NC shows the empty filter insert placed on top of the 3D 
model and then AuNCs-Anti-CRT applies onto empty CMC+gelatine 3D matrix. These images 
taken use new optimised confocal microscopy. 
 
 
3.20. Monitoring and localizing of AuNCs-Anti-CRT within 
spheroids  
 
Following the above experiments, HT29 and MCF7 grown spheroids were 
targeted using AuNCs-Anti-CR and then fixed to allow for further investigations 
of how the AuNCs-Anti-CRT interacted within the spheroids.  
 
3.20.1. AuNCs-Anti-CRT within HT29 spheroids  
 
The (Figure 3.54) below showed grown HT29 targeted spheroids after fixing 
process. AuNCs-Anti-CRT mostly is on edges, to the better understanding of 
this targeting (Figure 3.55) showed 3D view of this spheroid (from top to 
bottom). And (Figure 3.56) showed stacking view of this spheroid. AuNCs-Anti-





Figure 3.54: shows the single view of HT29 spheroid targeted using conjugated AuNCs. Uptake 




Figure 3.55: shows 3D view of the HT29 spheroid, targeted using conjugated AuNCs. Uptake 
appears more intense on the periphery/outer boundary and bottom layer of the HT29 spheroid. 





Figure 3.56: shows stacking view of the HT29 spheroid, targeted using conjugated AuNCs. it shows 
uptake appears more intense on the periphery/outer boundary and bottom layer of the HT29 
spheroid. Higher level of fluorescence (from top to bottom). Using fluorescence microscopy. 
 
3.20.2. AuNCs-Anti-CRT within MCF7 spheroids  
 
The (Figure 3.57) below showed grown MCF7 targeted spheroids after fixing 
process. AuNCs-Anti-CRT was seen mostly around the periphery/edges, to the 
better understanding of this targeting (Figure 3.58) showed 3D view of this 
spheroid (from top to bottom). And (Figure 3.59) showed stacking view of this 
spheroid. AuNCs-Anti-CRT is mostly on edges and bottom of the spheroid.  
 
 
Figure 3.57: shows the single view of the MCF7 spheroid targeted using conjugated AuNCs. uptake 






Figure 3.58: shows 3D view of the MCF7 spheroid, targeted using conjugated AuNCs. Uptake 
appears more intense on the periphery/outer boundary and bottom layer of the MCF7 spheroid. 
Using fluorescence microscopy. 
 
 
Figure 3.59: shows stacking view of the MCF7 spheroid, targeted using conjugated AuNCs. it 
shows uptake appears more intense on the periphery/outer boundary and bottom layer of the 












































4. Discussion:  
 
4.1. Basic growth characteristics of colorectal cancer cells and 
breast cancer cells in 2D flat cultures 
 
2D monolayer culture studies have been proven effective at the molecular and 
genetic level for demonstrating cancer cell behaviour and explaining the 
hypothesis of the mechanisms (97). To demonstrate the effectiveness of the 
alamarBlue assay for measuring cell proliferation and to define initial cell 
density at the beginning of the experiment, cell growth was monitored for both 
colorectal cells (HT29) and breast cancer cells (MCF7) over time. The results 
showed different seeded cell density from 5x103 cells/ml up to 50x103 cells/ml 
and how these correlated with fluorescence intensity increase. Hence these 
results defined the linear curve graph and the window of measurements.  
According to the linear alamarBlue curve 40x103 cells/ml was a peak point; 
therefore, 40x103 cells/ml was the highest optimum seeding density for HT29 
and MCF7. This is in line with published reports on 2D cultures from these cell 
lines, where seeding densities were in the range of 3x103 cells/ml to 100x103 
cells/ml for both HT29 and MCF7, depending on surface area seeded and time 
left to grow in culture before experimentation (98-100). 
 
4.2. Metabolic activity of colorectal cancer cells and breast 
cancer cells in 2D and 3D (A/E & A/C) 
 
To determine the optimum cell density in 3D for colorectal cells (HT29), cell 
proliferation as a direct reflection of metabolic activity was determined by 
alamarBlue assay. The lowest concentration of 25x103 cells/ml was not the 
appropriate density, Although the measurements slightly increased up to day 
seven after this cell viability was reduced, possibly due to the small number of 
cells not reaching critical mass in this protocol, indicating that the cells cannot 
grow and become a viable mass.  
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There is another possible explanation for this relating to the extracellular matrix, 
the interaction between the cells and their surrounding environment affects their 
matrix attachment and survival, proliferation and differentiation; hence cells 
start to die if not enough such events take place (101). At 50x103 cells/ml 
concentration, measurements slightly rose from day1 up to day10, however, 
due to not showing a perfect growth curve this could not be an optimum density 
for the experiment. 75x103 cells/ml resulted in an apparent increase from day 
one up to day ten. However, cells still did not reach the peak point compared to 
the higher concentration. For both matrix conditions, of A/C and A/E, 100x103 
cells/ml cells/ml showed perfect growth rate and measurements dramatically 
increased over time points indicating that the ratio of cells to environmental 
cues was optimum and enabled cell growth.  
For the breast cancer cells (MCF7), the cell proliferation and metabolic activity 
were determined by alamarBlue assay. The lowest concentration of 25x103 
cells/ml showed a slight increase up to day 10. Again, this indicates that cells 
could not provide support for their surrounding cells, in the context of a critical 
mass. This could be due to lack of formation of the extracellular matrix or lack 
of enough positive interactions with the existing matrix, which is essential for 
proliferation and differentiation (102). At 50x103 cells/ml and 75x103 cells/ml cell 
growth (as measured by alamarBlue) increased incrementally. However, the 
final concentration 100x103 cells/ml showed a definite increase, perfect linear 
growth curve and, as was chosen as the optimum seeding density.  
Colorectal (HT29) and breast (MCF7) cancer cell lines behave differently when 
cultured into 2D. Such as cell size, with HT29 cells smaller than MCF7 cells. 
The cell growth rate is size and cell cycle length dependent, therefore MCF7 
grow faster than HT29 in 2D and become confluent (103). The orientation with 
HT29 cells forming into glandular structures more obviously than MCF7 cells. 
The latter characteristic may be extrapolated to their tumorigenic ability in mice, 
with MCF7 being rather more tumorigenic (Estrogen supplementation required) 
than HT29 (104). Finally, gene expression has been well characterised in these 
cell lines, with, for example, HT29 carrying EGFR and BRAF mutations (105) 
and MCF7 carrying IGBP mutations (106).  
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Interestingly, both HT29 and MCF7 cell lines after being seeded in 3D in vitro 
models, they are maintaining all transcriptional and translational levels as 
occurs in vivo environment (20). Such as EGFR expression increase in 3D cell 
culture (107). 
 
4.3. Growth of cancer cells in different 3D matrices (tumouroids)  
 
Well-defined in vitro 3D models of cancer which mimic tumour structures and 
the heterogeneity of cell populations found in human cancer tissues and which 
allow cell-cell and cell-matrix relationships have caused excitement to the 
researchers because they can be used for a broad range of diagnosis and 
treatment purposes (108). Many various combinations have been described, 
especially in the last few years.  
The features of these 3D models have been studied from cell shape, cell 
division and multiplication, to gene and protein expression profiles of cells in 3D 
cell cultures (9). As collagen type-I is the most abundant extracellular matrix 
protein, a lot of 3D models use this as the basic protein or mix with other 
proteins (9) Collagen hydrogel embedded cells allow for both cell-cell and cell-
matrix interactions (109) and therefore, help promote the cancer cell 
multiplication rate.  
Some prominent examples which cover cancer and other diseases are 
tabulated below to demonstrate the large range of 3D models and approaches 
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Table 4.1: Examples of 3D in vitro models which mimic various pathologies, and their 
applications. 
 
Although using natural hydrogels of collagen type I is an attractive proposition, 
since it recapitulates an essential physiological component within the 3D model, 
there are some disadvantages, as the matrix does not allow for quickly 
harvesting the cells and/or spheroids embedded in it. To do this, it is necessary 
to treat the collagen matrix with enzymes such as collagenase which may be 
too disruptive (in house experience). 
Researchers even have suggested mixing two or three different gels to form 
composite gel matrix and to manipulate gel concentration, composition and 
mechanical properties for various applications (116). Therefore, two different 
“natural” gel forms were developed in this thesis and used to construct 3D 
models: The mixture of low melting point agarose with egg white (A/E) and the 
mixture of low melting point agarose with collagen type I (A/C).  
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Low melting agar was chosen, as agar has been used for decades in 
microbiology cultures and is known to provide a practical matrix for growth. 
There are reports which showed low melting agar as a potential polymer 
membrane to grow and transfer cells (117). Low melting point agarose modified 
to produce lower gelling and suitable recovery from low melting agarose gels. 
Therefore, this allows for ease of manipulation and help the matrix to set the 
gel and used in cell culture studies.  
The original concentration of collagen type I was 0.25 mg/ml, and after mixing 
with low melted agar, as the collagen type I were diluted further (1:2 ratio) 
hence, the final concentration was reduced to the half about 0.12/5 mg/ml. For 
comparison, initial concentrations reported in a plastic compression platform 
model (where an absorber or weight is placed on the hydrogel to remove water 
and increase density) was 0.25 mg/ml (115). To manipulate gel components 
and increase protein available to the cells low melted agar, at the same 
concentration as for the A/C matrix and egg white were mixed.  
There is a study that produced pre-vascular network formation by endothelial 
and smooth muscle cell co-culture using egg white. This matrix was appropriate 
for different human cell types, it is also enabled vascular and tumour cell co-
culture (43). 
 
4.4. HT29 colorectal cancer cells in 3D matrices – morphology in 
tumouroid cultures  
 
Colorectal cancer cells (HT29) were seeded at 100x103 cells/ml concentration 
in A/C matrices in 24 well plates, as described in the methodology chapter. 
Early on day 1 HT29 cells appeared to reside within the wells formed by the 
glass beads, with no sign of cell clumping or attachment. This could be due to 
the cancer cells needing to adapt to the new 3D environmental condition (118). 
Four days after cell seeding, the cells visibly started to grow/clump together in 
vitro, indicating they adjusted to their new surroundings. The collagen type I 
within the matrix is known to support 3D cell growth and differentiation, by 
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letting the cells to associate with one another, the ECM, and their molecular 
environment (31, 119). Specific interactions between cells and extracellular 
matrix proteins are known to drive growth and motility/migration (120). 
Specifically, for collagen type I, it has been reported that increase cell growth 
by protecting cancer cells from hypoxia and nutrient stress induced cell death 
that might occur in vivo-like (121). Collagen type I as a substance protein and 
helps the growth rate of cancer cells within A/C matrix (122). After that, cells 
continued to clump or aggregate and started to grow into spheroids over the 
timeline of the experiment, although a small number of spheroids were fully 
formed at day 10, with an average size range of 80 µm.  This was a lesser 
outcome than that seen for other matrices, as reported later in this section, 
suggesting that the A/C matrix is not the best. This could have been due to the 
limited amount of protein concentration within the A/C mixture compared to the 
A/E mixture. The collagen type I concentration is higher in compressed gel 
models, whereby applying a load or an absorber, the liquid is absorbed and 
produced a matrix with an increase in collagen density 1.28% and protein 
becomes more concentrated to 120 mg/ml (212).  
Colorectal cancer cells HT29 were introduced in the A/E matrix as described 
previously. At the early time point, day 1 HT29 cells were shown to reside within 
the wells formed by the glass beads. However, unlike the scenario in the A/C 
matrix, there were some signs of cell clumping and attachment. There were 
also some small spheroids already formed. The cell adaptation is essential in 
preserving the transcriptional and translational utilities in 3D (8). Four days after 
seeding, more spheroids appeared in different sizes. There were also fewer 
single cells observed in the A/E matrix compared to the A/C matrix. For the next 
time point at day, seven bigger spheroids formed and migrated outside the wells 
which influence tumour cell attachment and cells migratory capabilities. 
Although cells’ migratory abilities depend on the ECM architecture, as 
described above (123). And eventually, at the later stages, the large spheroids 
were evidently formed within the tumouroid cultures, with an average size of 
140 µm. There were fewer single cells in the A/E matrix compared to the A/C 
matrix, possibly due to the existence of ovalbumin or ovomucoid which increase 
the proliferation of cells in A/E condition (124) hence the spheroids formation is 
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much better than A/C condition. Further discussion on the egg white protein 
concentration is included in the next section.  
 
4.5. MCF7 breast cancer cells in 3D matrices – morphology in 
tumouroid cultures 
 
MCF7 breast cancer tumouroids were created in the A/C matrix, by the exact 
method described in methodology chapter, again using a concentration of 
100x103 cells/ml. At the first-time point (Day 1) MCF7 cells appeared to reside 
within the wells formed by the glass beads, with no sign of cell clumping and 
attachment, possibly to the lag time associated with changes and adaptation to 
the 3D environment, of transcriptional and translational levels (8). At next time 
point, (Day 4) cells started to aggregate. At day 7, cells gradually began to 
clump and hence started to grow into spheroids. Addition at the final time point, 
some of the spheroids fully formed, and some spheroids completely migrated 
outside the wells although some cells would simply not aggregate together. 
This could be due to the ECM architecture which plays a pivotal role when 
considering cancer cell invasion (125). In some highly dense collagen type-I 
structures for example the breast tissue, the cancer cells depend on 
membrane-bound MMPs to make a path via which destruction by other MMPs 
and migration of cancer cells becomes conceivable (126). The average 
spheroid size was 60 µm.  
MCF7 breast cancer tumouroids was also created in the A/E matrix, by the 
same method. At day 1, MCF7 cells appeared to reside within the wells formed 
by the glass beads, with some sign of cell clumping and attachment. At Day 4, 
there were some spheroids formed. This could be due to cell adaptation within 
the matrix, which is essential in supporting the transcriptional and translational 
functions in 3D (20). At day seven some spheroids and clumping cells started 
to migrate outside the wells. Eventually, at day ten 3D spheroids were fully 
formed, with only a few single cells appearing in A/E matrix when compared to 
the A/C matrix; also, the formation of spheroids was significantly higher than 
A/C matrix with a larger average size. This is possibly due to the existence of 
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ovalbumin or ovomucoid which increase the proliferation of cells in A/E 
condition (124). Hence, MCF7 spheroids formed well and more efficiently in A/E 
than the A/C matrix.  
The MCF7 cells survived better than HT29 cells in this matrix, indicating they 
are more robust or more aggressive cells. This reflects their behaviour in 2D, 
where MCF7 cells are larger cells and have a faster growth rate (127). And their 
behaviour in animal models, where MCF7 cells which result in moderately 
differentiated tumours in vivo can be termed as more tumorigenic than HT29 
cells which tend to produce well-differentiated cancers in vivo (128). HT29 have 
well-organized nuclei and exhibit robust cell-cell adhesion called round tumour 
(8). Non-invasive cells MCF7 remain as cell aggregates and do not invade into 
the surrounding invasion matrix, the 3D structure of MCF7 spheroids are 
disorganized nuclei and exhibit robust adhesion- called mass tumour (129). 
Generally, the pattern of growth was accelerated in A/E compared to A/C with 
earlier and bigger spheroids, resulting in large spheroids at the final time point 
for both colorectal cancer cells and breast cancer cells. This may have been 
due to stability of egg white ECM which allow cells to grow and migrate and 
organized themselves. The egg white composition consists of protein, trace 
minerals, fatty material, vitamins, and glucose. The main three proteins 
included in egg white composition that may potentially play a role in assisting 
the formation of cancer cells spheroids are Ovalbumin, Ovotransferrin, and 
Ovomucoid (124). This matrix (A/E) also has potential for vascular and tumour 
cell co-culture (43). Cells grown in egg white were showed better grow, migrate, 
and organize themselves as pre-vascular network and significantly higher cell 
density than in Matrigel. 3D culture models’ studies showed egg white is an 
alternative for Matrigel (43). 
Also, as it has described earlier in this chapter, there are reports were showed 
low melting agar as a potential polymer membrane to grow and transfer cells 
(117). The report also showed the cancer cells could be grown on plastic dishes 
using low melt agarose with an efficiency of 80–90% (117). 
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For growth and expansion and movement of the cells within the matrix, a 
degree of breaking down of the matrix may be needed via matrix 
metalloproteinases, however, this line of investigation was not undertaken in 
this body of work. The (MMPs) enzymes that degrade ECM components and 
allow spheroids invasion, an upsurge in MMP production rate improves 
invasiveness that is independent of cell–cell adhesion. The sustenance of 
invasion in dense matrices requires high MMP production rates (130). And their 
key actions have been demonstrated in several cancer types, including breast 
and colorectal. The rise in ECM density and the MMP inhibition effect reduced 
the migration of MCF7 cells embedded in sandwich gels (131). The colon 
cancer cell invasion and migration showed a correlation with increased in MMP-
1 gene expression, and these observations were reversed by chemical 
inhibitors or neutralizing antibodies against MMP-1 (132). 
 
4.6. Propagation of cancer cells as spheroids, in 3D A/E matrix 
 
To demonstrate whether cells could be passaged in 3D, spheroids for both 
HT29 and MCF7 were harvested from the tumouroid constructs by gentle 
centrifugation and reseeded, with a success rate. This was only attempted for 
the A/E matrix as this condition has more potential compared to the A/C 
condition due to the faster cell growth, and migration. Harvesting of spheroids 
and further manipulation is common for simple cancer spheroid models, such 
as spheroid drops. In such models, simple cancer spheroids grown in hanging 
drop cultures and incubated for certain time points prior to, for example, drug 
tests. Several interactions between cells and between cells and the matrix 





4.7. Manufacturing a novel synthetic-organic matrix for 3D 
tumouroids 
 
The above technique had an excellent rate of cell/spheroid survival however 
the 3D matrices are mechanically weak (7). Hence, to overcome these 
limitations, synthetic hydrogels can be considered as potential matrices. They 
are created specially to copy biomolecular organisations as seen in vivo, such 
as polylactide (PLA), polyglycolide (PGA) (134). Synthetic-organic matrices 
have stronger mechanical properties than natural scaffolds. Furthermore, 
synthetic polymer functionalization can also be achieved by adding scaffolds to 
specific ECM constituents to copy structures of the biological microenvironment 
and therefore providing physiological prompts to the cells to enhance growth 
and movement (135). 
Though, cell behaviour will still rely on various properties of these biomaterials 
including their chemistry, surface properties (hydrophobicity, hydrophilicity, 
topography) and structure (porosity, surface area, interconnectivity) (136). 
Therefore, as synthetic scaffolds are simply not made of natural components, 
to achieve an in vivo-like structure, with all the vital micro-environmental signs, 
is a complex and challenging task. Therefore, the next step was to design a 
new 3D model based on synthetic-organic matrices.  
 
4.8. The physical properties of the new 3D matrix (CMC+gelatine) 
 
Hydrogels have been the preferred matrix in establishing 3D models in cancer 
studies for its convenient preparation and cytocompatibility. Selecting the 
appropriate chemical composition of the matrix plays a significant role in the 
cell function control and cellular phenotype. These requirements have led to 
development of hydrogels derived from biological sources recently, as it closely 
resembles the microenvironment, suitable for 3D cultures (216). 
In these studies, CMC in combination with gelatine which is normally 
hydrolysed collagen type 1 was selected to create 3D hydrogel cultures of 
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colorectal and breast cancer cells. This format was selected for its physiological 
significance of collagen in the growth and maintenance of the cancer molecular 
environment. Constructing cellular new 3D model using a CMC+gelatine 
combination produced a matrix with different mechanical properties and 
composition although it was unknown how it would influence tumour cell 
attachment and migratory capabilities.  
Recent studies confirm the advantage of using gelatine that can promote cell 
proliferation (137). Due to its unique properties, gelatine is widely used in 
creating the gel, and in restructuring, stabilizing, emulsifying, and forming foam 
(138). Gelatine has also been investigated in 3D hydrogel using adipose tissue-
derived stromal cells (ADSCs), and it showed that cross-linked gelatine 
hydrogel promoted cell adhesion, proliferation, and differentiation (137). 
Furthermore, hormones can be added to the polymer mixture during the 
preparation stage to aid in the proliferation. Cells require growth factors to 
proliferate and differentiate in cell culture and usually more than one growth 
factor is required (139). Defining the physical properties of the novel mixture 
was deemed essential, therefore, viscosity level and water swelling capability 
of the solution were analysed. To achieve high degrees of swelling, it is usual 
to use synthetic polymers that are water-soluble when in non-cross-linked form 
(140). 
The combination of carboxymethyl cellulose with gelatine improved the 
mechanical properties of the mixture. In this study, the porous nature of the 
CMC/Gel hydrogels promoted the spatial structure for cell growth and 
proliferation, as observed by the development of 3D spheroids from the cancer 
cells grown within them. The spheroids generated are like those generated in 
standardised matrigel. Previous studies have indicated that physical properties 
of tissues can adopt the malignant behaviour (206, 207), by influencing cell 
properties, including morphology (208), proliferation (209) motility, 
differentiation, (210) and response to therapeutic agents (211). 
The water swelling capability of the novel matrix was checked to determine the 
amount of water that CMC can absorb using freeze-drying which is a 
dehydration process. The role of water molecules in affecting the structure and 
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the properties of CMC+gelatine regarding swelling capability was essential 
because it changes the structure of the CMC+gelatine and therefore due to its 
high water swelling abilities the samples of CMC are suitable for biological and 
medical applications (141). The amount of water in CMC+gelatine affects the 
rheological properties. The arrangement of water molecules inside 
CMC+gelatine can be considered a critical point in the understanding of 
CMC+gelatine rheological behaviour and therefore, the amount of water in both 
swollen and dried forms of CMC analysed. The increase of the swelling 
capability of CMC+gelatine can lead to a decrease in some of the mechanical 
properties of the CMC+gelatine, such as tensile strength (142). 
Another physical property which was investigated was the viscosity of the 
matrix fluid. The viscosity of solutions is indirectly related to temperature; 
therefore, the viscosity decreased with increases in temperature (143). A/E 
viscosity and A/C viscosity were higher than the novel matrix composed of 
CMC+gelatine, due to the existence in the natural matrices of low melting agar 
that helps the matrix to set the final gel (144). The results also showed 
CMC+gelatine viscosity was slightly higher than CMC solution alone (No 
gelatine) at room temperature. The viscosity level is critical, as it must not 
interfere with the 3D harvesting step. Here, the assumption was that the lower 
viscosity of the novel matrix would enable better spheroid harvesting than the 
natural matrices. 
 
4.9. Metabolic activity of cancer cells in the novel 3D matrix 
(CMC+gelatine) 
 
Many of cell seeding concentrations were tested over time to determine 
optimum conditions for growth. The lowest concentration of HT29 colorectal 
cancer cells 25x103 cells/ml showed a constant increase from day one up to 
day 7 and at day 10 dropped to less than 60%. Therefore, this concentration is 
not suitable for the experiment. The higher concentration 50x103 cells/ml 
showed solid, continuous growth curve of spheroids from day1 up to day10. 
The higher density 100x103 cells/ml of HT29 showed a similar growth curve to 
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50x103 cells/ml Both these concentrations were deemed suitable for further 
experiments. Eventually, at the highest density 150x103 cells/ml after normal 
increase up to day seven, the growth rate of spheroids stopped at day ten 
resulting in a dramatic drop in metabolic activity. This suggests that either the 
matrix and environment is not providing sufficient nutrients to the spheroids or 
that the size of the spheroids more than 250 was prohibitive and resulted in a 
hypoxic condition within the spheroids. The hypoxic condition is very size 
dependent, therefore larger spheroids are more hypoxic, as confirmed by the 
hypoxia studies in this report (145).  
The hypoxic condition in the 3D environment it could be the possible cause of 
a dramatic drop in this time point. This is consistent with previous publications 
where in other models, for instance, different colon cancer spheroids sizes were 
used displayed that cell interaction, hypoxia, and drug penetration limitations 
are suggested as possible causes for the massive spheroids resistance to 
photodynamic treatment. Spheroids of over 250 sizes have been shown to be 
hypoxic (145). 
A similar behaviour was seen for MCF7 breast cancer cells which were grown 
in the novel matrix., with 25x103 cells/ml resulting in dropped to less than 60% 
at day ten, therefore, this concentration is not suitable for the experiment. The 
higher concentrations of 50x103 cells/ml and 100x103 cells/ml resulted in an 
increase in metabolic activity from day one up to day 10 (with nicely formed 
spheroids, as described in the section below).   
Finally, at the highest concentration 150x103 cells/ml cells in 3D showed a 
dramatic increase from day one up to day four, and again continues increase 
up to day seven, followed by a dramatic drop from day seven up to day ten 
spheroids attached to each other and create a massive tumour with very 
hypoxic condition. The potential reason is the low level of oxygen in the 3D 
environment and the possibility of poor penetration of nutrients through the 
spheroid mass which occurs in spheroids with the size of approximately 250 
μm (145). 
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4.10. Growth and morphology of cancer cells in the novel 3D 
matrix CMC+gelatine matrix) 
 
The major difference between the synthetic organic novel matrix and the natural 
matrices appears to be one of tissue stiffness. Stiffness for natural hydrogels is 
not usually reported, as hydrogels are very loose structures, with (0.2% w/v) 
collagen density (212). On the other hand, the stiffness of CMC matrices has 
been reported as (without the gelatine), which is considerably higher (146). 
There are studies which suggest that stiffer matrices are more beneficial for cell 
growth, using primary normal human lung fibroblasts to modulated cytoskeletal 
tension in cells propagated across a physiological assortment of matrix 
stiffness, this report established reducing cell tension on proliferation and matrix 
stiffness efficiency (147). 
At day one, after seeding the colorectal HT29 and breast MCF7, small 
spheroids were already formed, this suggested that the cancer cells’ adaptation 
is faster in this matrix compared to the previous natural matrices (118). Four 
days later spheroids size dramatically increased due to the stable 3D 
environment and existence of gelatine (137). At day 7 HT29 spheroids growth 
rate reduced possibly due to cell contact effects and hypoxia and nutrition 
penetration (148). Limited nutrient and metabolic waste transport are an 
essential concern in 3D spheroid constructs because of a bulky ECM structure 
(149).  
At the final stage, high compact spheroids need to be harvested and transferred 
into the new 3D condition. It would be interesting to determine why this novel 
matrix appears to be more supportive of faster growth than the natural forms 
described above. All matrices contain varying amounts of protein, collagen, 
gelatine or large egg white proteins. Arguably, the egg white mixture has the 
highest protein content, however, this does not appear to be a determining 
factor in differential growth. 
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4.11. Growth of human umbilical vein endothelial cells in 
CMC+gelatine matrix. 
 
HUVECs were seeded into the 3D CMC+gelatine matrix and tracked over 
different time points for ten days. HUVECs have not shown any tube formation 
in CMC+gelatine matrix. However, at day10 HUVECs were transferred back 
into the 2D condition to determine cell viability. The results were showed 
HUVECs kept their normal growth rate and proliferation in 2D. It has been 
shown in other studies that well-matched substrates can help HUVECs 
tubulogenesis in 3D and that substrate stiffness affects the type and technique 
of tube formation in 3D (150). However, since this was not the pattern found in 
the CMC+gelatine model described here, the question raised is whether the 
addition of gelatine was the determining factor in the behaviour of the HUVEC 
cells. 
Additionally, different micro patterning methods applied to synthetic or 
composite matrices, growth factors, and adhesion molecules have been used 
to encourage HUVECs to form like tubes in vitro. Typically, there are two growth 
factors (BFGF, VEGF) associated with angiogenesis (151). Although, HUVECs 
usually make networks on compliant surfaces but not hard surfaces such as 
Matrigel and Egg white (43). The addition of BFGF and VEGF interrupt network 
formation and increase cell migration on soft surfaces (151). However, further 
investigation is required to determine the effect and interaction of growth 
factors, CMC+gelatine matrix, and cell migration and adhesions on network 
formation which are still uncertain. 
 
4.12. Live/Dead Evaluation (Propidium Iodide and FDA) of cancer 
spheroids in CMC+gelatine matrix 
 
The live/dead assay was used to determine spheroid viability in CMC+gelatine 
by tracking small spheroids from the early stage until they formed large 
spheroid structures. Spheroids grown in 3D CMC+gelatine model had normal 
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growth rate from day one up to day 5. The growth rate of spheroids from day 
five up to day ten was slightly reduced.  As a previous cell viability studies using 
alamarBlue assay have exhibited that there was no significant difference in cell 
viability in 3D monolayers in the course of the first few days (1–5 days) 
compared to 2D culture (8, 152). However, the structure of spheroids was 
showed mostly the internal structure of the spheroids surrounded by a layer of 
viable cells, which may cause the lack of oxygen and nutrients and the pile up 
of waste at the centre of the spheroid as they grow larger (149).  
There is a report that where the 3D hydrogel system made by the use of two 
cancer cell lines and a primary bone marrow mesenchymal stem line. And the 
results have shown, these 3D cell masses not only well-maintained cell viability 
and 3D morphology however also showed better cell function when matched to 
the similar 2D monolayer (153). 
 
4.13. Levels of oxygen/ Hypoxia of cancer spheroids in 
CMC+gelatine matrix.  
 
Hypoxia in spheroids grown in CMC+gelatine was measured by Hypoxia 
reagent at distinct time points of growth using a new automated confocal 
microscopy filter under development in the Department. No hypoxia was 
detected in matrices and spheroids for both HT29 and MCF7 at day one. There 
were indications that oxygen levels had started to drop to less than 5% from 
day four spheroids, although the latter were well formed (with average sizes 
around for HT29 & MCF7 respectively, 170 μm & 85 μm. This could be because 
HIF-1α expression had started to rise (154). There is a study were showed this 
overexpression is significantly related with MDR1 gene expression whose 
function is the ATP dependent export of substances from the inside of cells, 
and membranes, to the outside in colon cancer cells (213). At day 7, results 
have been shown to reduce spheroids growth rate with higher fluorescence 
intensity. Eventually, at day ten after certain time in 3D CMC+gelatine model, 
spheroids can develop hypoxic cores that can proceed to necrosis, closely 
mimicking what is seen in vivo (155) 
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Determining hypoxia within the spheroids is essential since it provides 
necessary information which underpins the growth and progression of the 
spheroids within any matrix, but also gives valuable information about the 
possible resistance of spheroids to treatment, such as, for example, 
photodynamic therapy and the usefulness of the spheroids as drug testing 
platforms. Similar hypoxic levels have been previously described with cancer 
spheroids of similar sizes for breast and colorectal cancer. By Validation of 
collagen type I 3D model using HT29 cancer cells which were used real time 
hypoxia measurements within a growing tumour (156) And characterise the 
gene expression changes linked with hypoxia in MCF7 and find a potential 
biomarker for hypoxia in breast cancer (157). Hypoxic regions may exist due to 
the difficulty of penetration of nutrients and oxygen and absence of a transport 
system to eliminate waste from the core of the spheroid. Its importance in 
response to drugs and radiation treatment has been widely described, and 
several attempts to increase response to treatment have involved the 
attempted reversal of hypoxia (158). 
 
4.14. Propagation of cancer cells as spheroids, in 3D 
CMC+gelatine matrix 
 
The isolated spheroids all showed a localised presence of calreticulin, a 
potential cancer marker, on their membrane surface when probed with targeted 
fluorescent gold nanoclusters. At day ten grown spheroids were ready to be 
harvested for further studies and replated within a matrix. There is a study that 
managed a simple microfluidic device for cell spheroid formation and spheroid 
harvesting (159). Harvested spheroids have high integrity (159). Hence, grown 
harvested spheroids are potential to be stained for targeting studies initially 
start with 2D fixed, and 3D fixed spheroids or eventually, for live precise 
targeting studies in 2D live and 3D live spheroids targeting by passing through 
endothelial cells. Harvested spheroids can also be exploited for more flow 
cytometry assays because of the sufficient cell numbers. 
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4.15.  AuNCs 
 
Biological imaging in vivo is faced with many more challenges than laboratory 
based cellular imaging. Interactions between the imaging molecule and the in 
vivo complex physiological environment may lead to its elimination before it 
reaches its target, and detection may be weak because of interference 
generated by the tissue components and the fact that in depth imaging is 
problematic with visible light (160). Therefore, new potential approaches are 
essential, both for molecules that can be used as imaging agents and for 
models which can be used to test these molecules. Several different nano 
scales signalling markers such as quantum dots and organic dyes have been 
used over the last few years for the purposes of imaging, (72) however: they 
often lack appropriate specificity and sensitivity and have the further 
disadvantages of high toxicity and low-stability (161). 
Au as a new class of fluorescent metal cluster which provides some advantages 
for in vivo imaging compared to other nanoparticles (162). AuNCs light 
emission is capable of penetrating into deeper tissue and sensing stronger 
intensity because of weakest biological auto fluorescence. Further advantages 
include good water-solubility, biocompatibility, and good photostability (163) 
Finally, there are possible applications of such nanoparticles which can deliver 
both imaging and enhanced cell killing (theranostic application) which makes 
the use of nanoparticles in cancer very attractive (164). Hence for this part of 
the study, AuNCs were manufactured in the house as nanoscale signalling 
markers for fluorescence imaging and tested first in 2D and then in 3D cancer 
cell models. 
 
4.16. Toxicity of AuNCs in 2D cultures of all cell lines. 
 
 
HT29, MCF7, and HUVECs cells were exposed to both AuNCs and HAuCL4 
equivalent concentrations. The results for all cell lines showed that HAuCL4 
conferred a much higher level of toxicity compared to AuNCs. A Recent study 
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has shown AuNCs with the large photostability as well as the reduced toxicity 
showed their potential for uninterrupted imaging in vivo (165). 
As it displayed the AuNCs fluorescence signal, the cell viability and toxicity 
studies reveal the nontoxic nature of AuNCs. These attractive characteristics 
including ultra- small size, decreased toxicity and reduced photo-bleaching 
make AuNCs even more appealing fluorescent probes for biological purposes. 
AuNCs could be simply could be detected by a fluorescent microscope (165). 
 
4.17. Targeting cells in 2D cultures (fixed), using AuNCs-Anti-
EGFR 
 
There are several studies which describe that the epidermal growth factor 
receptor (EGFR) is overexpressed in different types of cancers, such as 
subsets of colorectal cancer and breast cancer (166). Increased EGFR 
expression drives increase cell replication via the MAPK signalling pathway, 
and it is also associated with increased motility and the metastatic phenotype 
(167). Generally, EGFR has been targeted in a variety of cancers, with new 
generation biologics (antibodies) used in the clinic, including for colorectal and 
breast cancer (168). Therefore, overexpression of EGFR, detected by AuNCs 
conjugated to anti-EGFR antibodies was studied here, in both colorectal and 
breast cancer cells in 2D fixed cell cultures, to determine the suitability of the 
whole concept. The validation of the conjugation between nanoclusters and 
antibody was carried out by a colleague in blotting experiments and were not 
presented in this thesis.  
2D cultures of HT29 colorectal cancer cells were fixed and exposed to AuNCs 
conjugated to anti-EGFR antibodies (AuNCs-Anti-EGFR) or unconjugated 
AuNCs, with only the former cultures showing fluorescence and therefore 
uptake of the AuNCs-Anti-EGFR, this is consistent with previous work, which 
demonstrated that HT29 cells express EGFR (115, 169) and overexpression of 
EGFR in colorectal cancer cells could be a potential reason for that. 2D cultures 
of MCF7 breast cancer cells were fixed and exposed to AuNCs conjugated to 
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anti-EGFR antibodies (AuNCs-Anti-EGFR) or unconjugated AuNCs, with only 
the former cultures showing fluorescence and therefore uptake of the AuNCs-
Anti-EGFR. Other studies were showed that MCF7 cells express EGFR (170, 
171) Overexpression of EGFR in breast cancer cells could be a potential reason 
for that. 
Clinically, EGFR is targeted using the monoclonal antibody Cetuximab (172). 
This is often used for EGFR positive colorectal cancer patients. Some clinical 
trials in breast cancer have revealed that targeting EGFR increases the 
chemosensitivity of breast cancer cells (173). Therefore, more widespread 
EGFR-targeting could have a promising therapeutic role in breast cancer. 
Therefore, it is quite important to continue exploring ways of increasing and 
improving the targeting of such a promising biomarker.  
 
4.18. Targeting cells in 2D cultures (fixed), using AuNCs-Anti-CRT  
 
The second biomarker investigated for targeting using AuNCs was Calreticulin 
(CRT), a cytoplasmic calcium-binding protein (174). CRT is a multifunctional 
protein predominantly found in endoplasmic reticulum (ER) (175).  Usually, the 
protein appears to act as control chaperone by stopping the proteins that are 
misfolded from progressing to the Golgi apparatus [21]. CRT also acts as Ca2+ 
storage protein, therefore playing an essential role in the intracellular signal 
transduction systems and therefore in tasks such as cellular proliferation and 
cell death. It also acts as a nuclear hormone receptor gene transcription 
modulator (176). 
The results showed that CRT exists on the surface of cancer cells; its original 
labelling on cancer cell surface by anti-CRT conjugated AuNCs indicates that 
CRT translocates to the cell surface during carcinogenesis, perhaps causing 
immunotolerance of the malignant cells between other functions. There have 
been previous studies associating CRT to various cancers (177). AuNCs 
functioned as fluorescent bio-probes accurately identifying surface-bound CRT 
(178) Validation of the conjugation between the AuNCs and the anti-CRT 
antibody was carried out via dot blots, using increasing concentrations of “cold” 
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antibody. Experiments to determine the expression of CRT were conducted in 
both cancer cell lines, HT29 and MCF7 and in the endothelial cell line HUVEC. 
2D cultures of HT29 colorectal cancer cells and MCF7 breast cancer cells were 
fixed and exposed AuNCs to conjugated to anti-CRT antibodies (AuNCs-Anti-
CRT) or to unconjugated AuNCs, with only the former cultures showing 
fluorescence and therefore uptake of the AuNCs-Anti-CRT. This strongly 
suggests that HT29 cells overexpress CRT, as it described earlier in our 
previous report were indicated that CRT is present on the surface of cancer 
cells (176) and there is a study were showed that the calreticulin gene was over 
expressed in MCF7 human breast cancer cell lines (170). 
2D cultures of HUVECs endothelial cells were fixed and exposed to AuNCs 
conjugated to anti-CRT antibodies (AuNCs-Anti-CRT) or to unconjugated 
AuNCs, however, both conditions not showing any sign of fluorescence. This 
could be due to CRT has not expressed on the surface of HUVECs endothelial 
cells (176). The CRT is expressed on the surface of a tumour derived cells of 
the solid cancers investigated, in the absence of any form of induction (176). 
Other studies were showed that CRT expression levels in tumour tissues 
significantly higher than CRT levels compared to normal tissues (179). CRT 
has also shown to be an essential biomarker for bladder urothelial cancer 
detection (180). 
 
4.19. Targeting cells in 2D (live), using AuNCs-Anti-CRT and 
AuNCs 
 
The next stage was to target CRT in live cancer cells. The impact of CRT 
expression on cell proliferation depends on cancer cell types.  Live 2D cultures 
of HT29 colorectal cancer cells and MCF7 breast cancer cells were exposed to 
AuNCs conjugated to anti-CRT antibodies (AuNCs-Anti-CRT) or to 
unconjugated AuNCs, with only the former cultures showing fluorescence and 
therefore uptake of the AuNCs-Anti-CRT. 
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The imaging of targeted HT29 cancer cells using fluorescence microscopy 
revealed that AuNCs-Anti-CRT could identify and trace the CRT on live cells 
(176). Increasing the exposure time of AuNCs-Anti-CRT and AuNCs may 
eventually increase the uptake in live cells. The imaging of targeted MCF7 
cancer cells using fluorescence microscopy revealed that AuNCs-Anti-CRT 
could detect and trace the CRT mostly on the membrane surface of breast 
cancer cells (176) Although, this should be considered that if exposure time 
increase this may lead to uptake of AuNCs-Anti-CRT and AuNCs in live cells.  
The route of focus is imaging fluorescence and then at the same setting for light 
transmission images. However this is only true for the cells that bound the 
AuNCs-Anti-CRT (top row). As the fluorescence was evident in the cells below 
focusing took place under light transmission. Therefore the field of focus and 
penetration under light transmission different for the top row.  
In effective drug development understanding of drug uptake and diffusion within 
tissues is an essential feature (181). Previous studies were exposed spheroids 
more precisely replicate in vivo barriers to drug uptake and diffusion than 2D 
cell culture system. The 3D models may be useful for the drug toxicity assays 
as well as a model for drug development (182). 
 
4.20. Targeting 3D fixed spheroids using AuNCs-Anti-CRT and 
AuNCs  
 
The effectiveness of AuNCs-Anti-CRT targeting in 2D cancer cells was 
examined under both live and fixed conditions. The results showed the 
specificity of targeting cancer cells using AuNCs-Anti-CRT. However, using 3D 
models could be a complementary, more powerful option which may give 
results closer to the in vivo scenario (9). The 3D culture systems not only keep 
the 3D cell to cell associations and cell to ECM interactions in monoculture for 
studying cell behaviour that mimics in vivo conditions, but 3D models also 
provide an opportunity for the co-culture of multiple types of cells to more 
closely mimic the in vivo conditions (31). The goal of using 3D models is to 
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develop and design, fast, precise, and reproducible high-content imaging 
techniques to examine the properties and fate of AuNCs-Anti-CRT within a 3D 
tissue mimic and their effect on the morphology and viability of 3D spheroids 
which are closer to cancer islands and glands observed in human cancer 
tissues (183). 
At day10 HT29 spheroids grown in CMC+gelatine matrix was harvested and 
fixed and incubated with AuNCs-Anti-CRT. This showed uptake of the targeted 
AuNCs-Anti-CRT, as demonstrated by the NIR fluorescent (false red colour) 
images. Uptake appeared more intense on the periphery/outer boundary of the 
spheroids consistent with CRT overexpression. At the same time, control 
experiments where fixed HT29 spheroids were incubated with AuNCs showed 
a reduced uptake of the AuNCs, as demonstrated by the red fluorescent 
compared to spheroids incubated with targeted AuNCs-Anti-CRT. This distinct 
labelling on the spheroid surface by anti-CRT conjugated AuNCs suggests that 
CRT translocates to the cell surface during carcinogenesis (176). DAPI 
fluorescence was used to identify of cell nuclei and describe well-populated 
spheroids. The results also indicated more cells towards the periphery of the 
spheroid, and fewer cells at the core of the spheroid. 
At day10 MCF7 spheroids grown in CMC+gelatine matrix was harvested and 
fixed and incubated with AuNCs-Anti-CRT. This showed uptake of the targeted 
AuNCs-Anti-CRT, as demonstrated by the NIR fluorescent (false red colour) 
images. Uptake appeared more intense on the periphery/outer boundary of the 
spheroids consistent with CRT overexpression. At the same time, control 
experiments where fixed MCF7 spheroids were incubated with AuNCs showed 
a reduced uptake of the AuNCs, as demonstrated by the red fluorescent 
compared to spheroids incubated with targeted AuNCs-Anti-CRT. This distinct 
labelling on the spheroid surface by anti-CRT conjugated AuNCs suggests that 
CRT translocates to the cell surface during carcinogenesis (176). DAPI 
fluorescence was used to identify of cell nuclei and describe well-populated 
spheroids. The results also indicated more cells towards the periphery of the 
spheroid, and fewer cells at the core of the spheroid.  
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Well-populated spheroids and all cell nuclei were identified based on DAPI 
fluorescence, with probably more cells towards the periphery of the spheroid, 
and fewer cells at the core of the spheroid, which determines to target, 
displayed by red fluorescence. There are studies where nanoparticles were 
used specially to target the cancer cells. To regulate gene expression, in MCF7 
cancer cells, the nanoparticle-conjugated TFO were delivered directly into the 
nucleus of MCF7 cancer cells using ultra-small gold nanoparticles (184). 
Another report has shown the direct visualization of interactions between drug-
loaded nanoparticles and the cancer cell nucleus (185).   
Studying of gold nanoparticles in two-dimensional (2D) and three-dimensional 
(3D) cell cultures have shown HT29 cancer cells taken up most of the 
nanoparticles with FA and the targeting nanoparticles have more 
correspondence to cancer cells than the pure drugs and untreated 
nanoparticles (186). These new approaches revealed that increased 
therapeutic effectiveness could provide new plans were provided to choose 
appropriate nano-carriers for targeted therapy. The penetration of gold 
nanomaterials is essential in molecular level, current studies revealed that 
penetration of gold nanomaterials through the membrane is size dependent 
hence, if gold nanomaterials is smaller than 3 nm, the AuNCs have great 
properties because of their ultrafine dimension and unique form The AuNCs 
light emitting is efficient to penetrate within tissue and shows stronger intensity 
detection (214), which directly affects the uptake time in targeted therapy (187).  
 
4.21. Targeting live cancer spheroids through an endothelial cell 
barrier in a complex tumouroid construct, using AUNCs-anti-
CRT 
 
Having shown appropriate targeting capabilities of the AUNCs-Anti-CRT 
molecules, using variously fixed and live cell cultures, the purpose of this 
section was to investigate whether targeted AuNCs would differentiate their 
targets within a more complex 3D construct, which incorporates an endothelial 
barrier. Both HT29 and MCF7 live spheroids were grown as above and placed 
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in a new matrix, with a filter insert on top seeded with a monolayer of HUVECs. 
The cancer spheroids were targeted using conjugated AuNCs-Anti-CRT which 
had to traverse the filter. Control groups included filter barriers with no 
endothelial cells on them. Imaging was carried out 2 h later, using fluorescence 
microscopy. Comparisons focused on the effect of the endothelial cell 
populated filter barrier.  
The cancer spheroids targeted by passing through HUVECs seeded filter 
inserts, showed higher fluorescence intensity compared to the empty filter 
insert condition. This shows the appropriate regulation of HUVECs as an 
endothelial barrier, which selectively absorbs fluid and solutes (188). Fluid, 
solutes, and even circulating cells can cross the basement membrane through 
two different routes, the transcellular pathway (cell body) and paracellular 
pathway (between the cells). Naturally, HUVECs grown on a 2D surface such 
as a filter insert, tend to form cord-like structures (189). 
Several pathways allow AuNCs-Anti-CRT to pass through an endothelial barrier 
to target spheroids within the matrix. The transcellular is one of the potential 
pathways.  The mechanism includes vesicle-mediated endocytosis at the 
endothelial luminal membrane, followed by transcytosis across the cell, and 
exocytosis at the basolateral membrane (190, 191).  There is also another 
possible reason for the higher fluorescence intensity of targeted spheroids as 
follows; Aquaporins are membrane proteins expressed in endothelial cells 
(192). They are important for the control of water homeostasis by providing 
selective passage for the rapid movement of water, and other uncharged 
solutes such as AuNCs, across diverse cell membranes (193). 
The blood-brain boundary prohibits the passage of most treatment agents into 
the brain (194). The studies have shown that the gold nanoparticles are 
potential to pass through human brain endothelium and then to enter 
astrocytes. The nanoparticles have the correct properties for effective and 
particular therapeutic agent’s carriers within the blood-brain barrier (195). This 
could be further investigated in vivo as a platform for targeted cancer therapies. 
 
 121 
4.22. Monitoring and localizing of AuNCs-Anti-CRT within 
spheroids  
 
Following the above experiments, HT29 and MCF7 spheroids were targeted 
using AuNCs-Anti-CR and then removed from the matrix and the filter and fixed 
to allow for further investigations of how the AuNCs-Anti-CRT interacted within 
the spheroids. After imaging using fluorescence microscopy, both cancer cell 
spheroids showed similar results with the AuNCs-Anti-CRT mostly on the outer 
edges and bottom of the spheroids.   
Further consideration needs to compare targeting studies in 2D cultures and 
3D spheroids. CRT expressed on the cell surface, in other words non-ER CRT 
is considered as a signal for cancer cells by anti-phagocytic signal CD47 (196). 
It has been previously described that an antiphagocytic signal CD47 was 
increased with high amounts of CRT on cancer cell surfaces to avoid 
phagocytosis by the immune system (196). Therefore, the ability of the CD47 
by anti-CD47 antibodies might be therapeutic to the cell phagocytic uptake 
(197). The results are an indication that CRT mediated immune responses is 
an important link to the development of new anticancer therapy.  
The expression of CRT in 2D appears uniform, while in 3D it appears on the 
outer boundary of the spheroid (198).The targeting 3D view and Z stacking view 
of both HT29 and MCF7 spheroids confirm the difference with 2D cultures, to 
determine whether the latter is a true picture, that the outer surface expression 
of CRT in spheroids is a true phenotype, other investigations must take place, 
such as immunohistochemistry and immunofluorescence using different 
antibodies to verify the present findings. Unfortunately, this was not carried out 
due to time constraints.  In another study, it was showed that powerful 
prognostic biomarkers were a constituent of CRT expression and were 
responsible for the enhanced local anti-tumour immune response in the lungs 
(199). 
 Overall, overexpression of non-ER CRT and the attachment efficiency of 
AuNCs-Anti-CRT to this CRT may be different in 3D and 2D cultures due to 
differences in phenotype of cancer cells while as a monolayer, or as a spheroid. 
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Further study has also shown the influence of the ECM on cancer growth where 
EGFR used colorectal cancer cells and gene expression were different in 2D 
and 3D cultures (107). This demonstrates strongly that using 3D models is 
different than using 2D models and may be a truer representation of the in vivo 
situation. The further investigation also confirmed CRT expression in human 











































5. Future prospective and conclusion: 
 
To date, most methods describing 3D cell culture systems for diagnostic or drug 
testing have been mainly recognised as a proof-of-concept approach. Majority 
of the knowledge obtained so far are the advantages over other types of 3D 
construction, potential anti-cancer drug evaluation compared to 2D systems. 
The use of 3D cell culture systems for diagnostic characterisation and 
evaluating novel anti-cancer drugs has yet to be translated to the mainstream. 
However, with the popularity amongst researchers in 3D systems and 
numerous availability of 3D matrices, data obtained will almost incorporate with 
2D and animal studies. 
While different types of 3D matrices are widely accessible to most researchers, 
standardisation and a universal system is needed whereby data are 
reproducible and reliable. Majority of the 3D systems are rigid and are difficult 
in the quantification of drugs or imaging due to the presence of the matrices.  
Pharmaceutical and clinical biopsies could benefit immensely using universal 
3D matrices to screen novel therapeutics for anti-cancer activities. Drug 
efficacy data obtained would be more physiologically relevant than data 
obtained from 2D monolayer culture system.  
Additionally, the 3D cell culture system is inexpensive and robust compared to 
animal trials. Weakly adherent cells can sometimes be rescued in 3D systems 
and qualify for drug screenings without loss of cells as would in 2D monolayer 
system. Currently, improved development in cultured liver cells (hepatocytes) 
in 3D to test the liver toxicity of novel therapeutics have been established. It is 
known that hepatocytes rapidly halt synthesising drug metabolising enzymes 
when cultured on 2D monolayer, however, in 3D format, these cells retain these 
function (217, 218). 
Another potential application of 3D drug sensitivity study is in the expanding 
field of personalised medicine. The treatment and prevention of cancer has 
greatly benefitted from introduction of personalised medicine, with genetic 
evaluation of genes, such as breast cancer (BRACA) 1 and 2 mutations, the 
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detection of the expression of certain proteins that can tailor effective therapies 
such as human epidermal growth factor receptor 2 (HER2) expression. The 
application of 3D matrices for the future could include tumour biopsies directly 
transferred, cultured and treated with and array of anti-cancer drugs. With 
universal standardisation and replicable matrices, 3D drug selection and 
imaging can be a potential solution to cancer therapy.    
For any type of cancer, cancer theranostics is an important field. There have 
been many advances in this field. The current cancer therapeutics procedures 
for cancer patients’ and supportive care, makes cancer therapeutics 
procedures a vital tool for oncologists and all professionals involved in cancer 
treatment. For the scientists one of the most potential method is using 
nanoparticles in cancer theranostics, hence, the use of nanoparticles become 
a priority in cancer theranostics.  
The latest studies show that the 3D cell culture models in vitro are potentially 
the strong tool for the early stage of cancer theranostics, before in vivo studies 
and eventually clinical trials. During this research study, the hydrogel culture 
matrix was made of CMC+gelatine as a 3D model for studying the growth and 
potential drug targeting of cancer cells. The use of carboxymethylcellulose 
(CMC) porous as a component in a binary system was successfully prepared 
by an aqueous system. The porous structure was fine-tuned by altering the 
composition of the CMC and gelatine in water. When polymerised under 
heating it could be saturated with growth medium for 3D culture growth. On top 
of that, it produced excellent thermal and swelling because the liquid medium 
is well retained in the CMC polymer matrix because of the presence of -OH and 
-COOH groups.  
Once tuned, the chemical and physical properties of the hydrogels give a basis 
for the analysis of the native cancer cell molecular environment. The main 
characteristics of breast and colorectal cancer cells grown in the matrix were 
compared with 2D monolayer cultures. For the first time, it has been shown that 
3D spheroids can be harvested and isolated from the matrix for evaluation of 
cancer markers by targeting with fluorescent gold nanoclusters. In the future 
two possible ways  
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1. Use this novel 3D matrix but change the biological material  
 
• Collected ex-vivo biopsies could be transferred directly into matrix and 
grown in the laboratory. 
•  Diagnose and further culture and then treat with various anti-cancer 
drugs to determine response.  
• Evaluate the current status of the disease progression using the 
underlying mechanisms.   
This would be an approach to personalized medicine. 
2. To increase the complexity of the existing model to be able to investigate 
interactions and cross-talk with immune derived cells such as Monocytes 
This model is flexible and components and cells can be separated for 
molecular investigation. Such an immunocompetent model would be 
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Figure 1.4: Tumour development from Stage 0 until stage IV   
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